📘

Definitions

1

Clinicopathologic definition

Vulvar carcinoma is a vulvar epithelial cancer, most commonly squamous cell carcinoma, diagnosed by biopsy of a suspicious vulvar lesion and staged with clinical, pathologic, and imaging assessment of local and nodal disease.

CASE_DEFINITION General adult gynecologic oncology definition

Show evidence (2 references)

PMID:38791925 SUPPORT Human Clinical

"Vulvar carcinoma is a rare cancer affecting the genital tract, constituting 4% of gynecological tumors. Vulvar squamous cell carcinoma (VSCC) is the most common type. Diagnosis relies on biopsy during vulvoscopy, plus imaging such as ultrasonography (USG), magnetic resonance imaging (MRI) and..."

This review defines vulvar carcinoma as a rare gynecologic cancer, identifies VSCC as the most common type, and summarizes biopsy and imaging-based preoperative assessment.

DOI:10.1055/a-1545-4279 SUPPORT Human Clinical

"The 2020 WHO classification is focused on the distinction between HPV-associated and HPV-independent squamous cell carcinoma of the lower female genital organs."

The WHO classification review supports HPV-associated versus HPV-independent classification for lower female genital squamous cell carcinoma, including vulvar squamous carcinoma.

◆

Subtypes

3

HPV-associated vulvar squamous cell carcinoma

Molecular subtype associated with high-risk human papillomavirus, p16 block staining and commonly non-keratinizing morphology, with generally better prognosis than HPV-independent disease.

Show evidence (2 references)

PMID:37840151 SUPPORT Human Clinical

"Vulva squamous cell carcinoma (VSCC) develops through two separate molecular pathways-one involving high-risk human papilloma virus infection (HPV-associated), and the other without HPV infection (HPV-independent) often involving TP53 mutation. HPV-associated VSCC generally has a better..."

The cohort paper directly supports HPV-associated VSCC as a distinct molecular pathway and links it to better progression-free survival.

DOI:10.1055/a-1545-4279 SUPPORT Human Clinical

"HPV-associated VIN (usual VIN; u-VIN), b and c non-keratinizing, HPV-associated squamous cell carcinoma of the vulva with a plump pattern of invasion and p16 positivity (so-called block staining; see text)"

The WHO review directly links the HPV-associated precursor and carcinoma pathway to p16 block positivity and non-keratinizing VSCC morphology.

HPV-independent TP53-altered vulvar squamous cell carcinoma

Molecular subtype not driven by HPV, commonly keratinizing, enriched for TP53 alteration and other somatic lesions, and linked to differentiated VIN in a chronic inflammatory vulvar-skin context.

Show evidence (3 references)

PMID:37840151 SUPPORT Human Clinical

"Vulva squamous cell carcinoma (VSCC) develops through two separate molecular pathways-one involving high-risk human papilloma virus infection (HPV-associated), and the other without HPV infection (HPV-independent) often involving TP53 mutation."

This abstract explicitly distinguishes the HPV-independent pathway and notes frequent TP53 mutation involvement.

DOI:10.1055/a-1545-4279 SUPPORT Human Clinical

"HPV-independent VIN (d-VIN), e and f keratinizing squamous cell carcinoma of the vulva with a netlike pattern of invasion and aberrant p53 expression (see text)."

The WHO figure caption directly connects dVIN with keratinizing VSCC and aberrant p53 expression in the HPV-independent pathway.

DOI:10.3390/cancers16244216 SUPPORT Human Clinical

"those that arise independently of HPV (HPVi), most commonly in the setting of a chronic inflammatory condition of the vulvar skin. This latter group of HPVi VSCC arises in most cases secondary to mutations in TP53"

The review directly links most HPV-independent VSCC to a chronic inflammatory vulvar-skin context and TP53 mutation.

HPV-independent p53-wild-type vulvar squamous cell carcinoma

Uncommon HPV-independent molecular subtype lacking abnormal p53 immunophenotype, with intermediate prognosis between HPV-associated and HPV-independent TP53-altered disease.

Show evidence (2 references)

DOI:10.3390/cancers16244216 SUPPORT Human Clinical

"This latter group of HPVi VSCC arises in most cases secondary to mutations in TP53, but recently, attention has focused on the uncommon TP53 wild-type HPVi VSCC."

The review explicitly identifies HPV-independent TP53-wild-type VSCC as an uncommon third molecular subgroup.

DOI:10.3390/cancers16244216 SUPPORT Human Clinical

"HPVa VSCC has the most favorable prognosis, while HPVi VSCC with TP53 mutations (p53abn) has the worst prognosis, and HPVi VSCC with wild-type TP53 (p53wt) has an intermediate prognosis."

This directly supports the intermediate prognosis assigned to the HPV-independent p53-wild-type subgroup.

?

Discussions and Knowledge Gaps

1

Is cancer-associated-fibroblast dependence a shared invasion mechanism across HPV-associated, HPV-independent p53-abnormal, and HPV-independent p53-wild-type VSCC, or is the VCC1 result specific to one lichen-sclerosus-associated tumor model?

KNOWLEDGE GAP OPEN gap_vulvar_carcinoma_caf_model_subtype_generality

Attached to

pathophysiology#Fibroblast-Supported Tumor Invasion experimental_models#VCC1 Lichen-Sclerosus-Associated VSCC Cell Line

The current experimental evidence comes from one spontaneously immortalized lichen-sclerosus-associated cell line studied in organotypic culture and xenografts. That model supports stromal dependence in VCC1 but cannot by itself establish generality across the three molecular VSCC subtypes or distinguish patient-specific from subtype-shared fibroblast effects.

Proposed experiments

Subtype-stratified patient-derived VSCC organoid and CAF perturbation panel

patient-derived tumor organoid coculture perturbation experiment

exp_vscc_subtype_stratified_organoid_caf_panel

Establish multiple patient-derived tumor organoids from each major VSCC molecular subtype and compare matched CAF addition, depletion, and cross-over coculture under a harmonized invasion assay.

Model systems

Subtype-stratified patient-derived VSCC organoid-CAF coculture panel

Replicate organoid lines from HPV-associated p16-positive, HPV-independent p53-abnormal, and HPV-independent p53-wild-type tumors, each paired with matched primary CAFs and normal-vulvar fibroblasts.

CO CULTURE

human NCBITaxon:9606

vulva UBERON:0000997

vulvar squamous carcinoma cell CL:0000312 cancer-associated fibroblast CL:0000057

Perturbations

Matched CAF addition or depletion

pathophysiology#Fibroblast-Supported Tumor Invasion

Compare tumor organoids with matched CAFs, without fibroblasts, and with normal-vulvar fibroblasts to isolate stromal dependence.

Cross-subtype CAF exchange

pathophysiology#Fibroblast-Supported Tumor Invasion

Exchange CAFs among molecular-subtype organoids to distinguish a shared fibroblast program from subtype-matched or patient-specific effects.

Readouts

Three-dimensional invasion and organoid growth

pathophysiology#Fibroblast-Supported Tumor Invasion

Quantified invasion distance, invasive area, and organoid growth over time.

three-dimensional invasion assay

Direction: POSITIVE

Histologic and transcriptional stromal-response fidelity

pathophysiology#Fibroblast-Supported Tumor Invasion

Keratinizing morphology, epithelial-mesenchymal-transition markers, and single-cell tumor/CAF programs compared across subtypes and conditions.

histopathologic assessment single-cell transcriptomic profiling

Direction: POSITIVE

Controls

Tumor organoid without fibroblasts

Establishes the fibroblast-independent invasion and growth baseline for each patient line.

Normal-vulvar fibroblast coculture

Distinguishes a cancer-associated fibroblast effect from nonspecific stromal support.

VCC1 organotypic benchmark

Reproduces the published single-line result as a positive benchmark without treating it as subtype-representative.

Decision criterion

A shared CAF-dependence mechanism is supported if CAF addition reproducibly increases invasion across independent lines in all three subtypes and CAF depletion reverses it relative to matched controls. Subtype restriction is supported if the effect replicates only within one molecular group; failure to reproduce beyond VCC1 would refute cross-subtype generality.

Would support

pathophysiology#Fibroblast-Supported Tumor Invasion

Show evidence (2 references)

PMID:31654625 SUPPORT In Vitro

"In vitro 3D organotypic assays and in vivo xenografts revealed a prominent role of cancer-associated fibroblasts in VCC1 invasion and tumor formation."

The organotypic arm motivates the gap by demonstrating CAF-dependent VCC1 invasion in vitro while leaving cross-subtype reproducibility untested.

PMID:31654625 SUPPORT Model Organism

"In vitro 3D organotypic assays and in vivo xenografts revealed a prominent role of cancer-associated fibroblasts in VCC1 invasion and tumor formation."

The xenograft arm motivates the same gap by demonstrating CAF-dependent VCC1 tumor formation in vivo while leaving cross-subtype generality untested.

⚙

Pathophysiology

13

High-Risk HPV Infection

High-risk HPV infection defines one major etiologic pathway of vulvar squamous cell carcinoma and precedes viral-oncoprotein disruption of host tumor-suppressor control.

vulvar keratinocyte CL:0000312

response to virus GO:0009615

vulva UBERON:0000997

Downstream

HPV E6-Mediated p53 Degradation Oncogenic HPV infection permits expression of E6, which targets p53.

HPV E7-Mediated pRB Binding Oncogenic HPV infection permits expression of E7, which binds pRB.

HPV-Associated High-Grade Squamous Intraepithelial Lesion (HSIL/uVIN) Persistent high-risk HPV infection defines the HPV-associated high-grade vulvar precursor pathway.

Show evidence (1 reference)

PMID:37840151 SUPPORT Human Clinical

"Vulva squamous cell carcinoma (VSCC) develops through two separate molecular pathways-one involving high-risk human papilloma virus infection (HPV-associated), and the other without HPV infection (HPV-independent) often involving TP53 mutation."

The human tumor cohort identifies high-risk HPV infection as one of the two principal molecular pathways of VSCC.

HPV E6-Mediated p53 Degradation

The high-risk HPV E6 oncoprotein binds p53 and stimulates its degradation through the ubiquitin-dependent protease system, weakening a central tumor-suppressor checkpoint in infected vulvar keratinocytes.

vulvar keratinocyte CL:0000312

TP53 hgnc:11998

proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043161 ↑ INCREASED

Downstream

Clonal Squamous Cell Proliferation Loss of p53-mediated restraint permits survival and expansion of damaged keratinocytes.

Show evidence (2 references)

PMID:2175676 SUPPORT In Vitro

"In this study we demonstrate that the E6 proteins of the oncogenic HPVs that bind p53 stimulate the degradation of p53."

This classic mechanistic study directly supports E6-mediated p53 degradation rather than inferring tumor-suppressor disruption from p16 staining alone.

PMID:25340830 SUPPORT Other

"The HR HPV E6 protein induces ubiquitin-mediated degradation of p53, resulting in disabling of the normal cellular response to many insults, including the DNA damage response"

This viral-carcinogenesis review connects E6-mediated p53 degradation to loss of the host DNA-damage response modeled by this node.

HPV E7-Mediated pRB Binding

The high-risk HPV16 E7 oncoprotein binds the retinoblastoma protein pRB, disrupting RB-pathway control and enabling inappropriate cell-cycle entry in infected vulvar keratinocytes.

vulvar keratinocyte CL:0000312

RB1 hgnc:9884

G1/S transition of mitotic cell cycle GO:0000082 ↑ INCREASED

Downstream

Clonal Squamous Cell Proliferation E7-associated loss of RB restraint promotes transformed keratinocyte proliferation.

Show evidence (3 references)

PMID:2537532 SUPPORT In Vitro

"These assays have been used to demonstrate that the E7 oncoprotein of the human papilloma virus type-16 can form similar complexes with p105-RB."

The biochemical study directly demonstrates HPV16 E7 binding to the RB gene product and supports RB-pathway disruption in HPV-associated cancer.

PMID:25340830 SUPPORT Other

"E7, another HPV oncogene, mimics this process by binding to pRB and releasing the E2F protein"

The review directly supports the modeled step from E7-pRB binding to E2F release.

PMID:25340830 SUPPORT Other

"This results in the release of the E2F protein, which then activates the transcription of genes required for the S-phase transition"

The same review connects E2F release to transcriptional activation of the S-phase program, supporting increased G1/S transition in this node.

Lichen Sclerosus Inflammatory Microenvironment

Lichen sclerosus creates chronic vulvar inflammation, tissue remodeling, oxidative stress, scarring, and symptoms that can precede or accompany HPV-independent vulvar squamous carcinogenesis.

vulvar keratinocyte CL:0000312

extracellular matrix organization GO:0030198 ⚠ ABNORMAL

vulva UBERON:0000997

Downstream

HPV-Independent Somatic Driver Accumulation Chronic inflammatory and oxidative injury can create a permissive context for somatic driver selection.

Vulvar Pruritus Lichen sclerosus commonly produces vulvar itching.

Vulvar Pain or Soreness Lichen sclerosus commonly produces vulvar soreness and pain.

Differentiated Vulvar Intraepithelial Neoplasia (dVIN) Lichen sclerosus can provide a clinical context for the HPV-independent differentiated precursor pathway.

Show evidence (2 references)

DOI:10.3389/fmed.2023.1106318 SUPPORT Human Clinical

"Oxidative stress with lipid and DNA peroxidation provides an enabling microenvironment to autoimmunity and carcinogenesis."

The review supports oxidative stress and immune-mediated tissue injury as a carcinogenesis-enabling microenvironment in lichen sclerosus.

DOI:10.3389/fmed.2023.1106318 SUPPORT Human Clinical

"In addition to genital scarring, and sexual and urinary dysfunction, LS may also lead to squamous cell carcinoma."

This explicitly links lichen sclerosus to squamous cell carcinoma risk.

HPV-Associated High-Grade Squamous Intraepithelial Lesion (HSIL/uVIN)

HPV-associated high-grade squamous intraepithelial lesion, historically usual-type VIN (uVIN or VIN 2/3), is the HPV-associated vulvar precursor. Compared with dVIN it generally has slower progression, and spontaneous regression can occur in the HPV-associated VIN spectrum.

vulvar keratinocyte CL:0000312

epithelial cell proliferation GO:0050673 ↑ INCREASED

vulva UBERON:0000997

Downstream

Clonal Squamous Cell Proliferation HPV-associated HSIL/uVIN can progress through further clonal expansion toward invasive carcinoma.

Show evidence (2 references)

DOI:10.1055/a-1545-4279 SUPPORT Human Clinical

"With reference to vulvar intraepithelial neoplasias (VIN), the distinction between HPV-associated and HPV-negative neoplasia has been retained. In terms of nomenclature, HPV-associated VIN corresponds to low (VIN 1) and high-grade SIL (VIN 2 and 3;"

The WHO review maps HPV-associated VIN 2/3 to high-grade squamous intraepithelial lesion, supporting this precursor as distinct from dVIN.

DOI:10.1055/a-1545-4279 SUPPORT Human Clinical

"Spontaneous regression possible (especially VIN 1) Most common form of VIN Slower rate of progression squamous cell carcinomaVIN"

The WHO clinicopathologic figure supports slower progression and possible spontaneous regression in the HPV-associated VIN spectrum; the entry does not infer a numerical progression risk from this qualitative evidence.

Differentiated Vulvar Intraepithelial Neoplasia (dVIN)

Differentiated VIN is an HPV-independent precursor that occurs in older women and can arise in a lichen-sclerosus context. It has no expected spontaneous regression, progresses more rapidly than HPV-associated VIN, and is allocated to the more aggressive keratinizing squamous carcinoma pathway.

vulvar keratinocyte CL:0000312

epithelial cell proliferation GO:0050673 ↑ INCREASED

vulva UBERON:0000997

Downstream

Clonal Squamous Cell Proliferation dVIN can progress through clonal expansion toward keratinizing invasive carcinoma.

Show evidence (3 references)

DOI:10.1055/a-1545-4279 SUPPORT Human Clinical

"The differentiated VIN with its horizontal spread (d-VIN) is a precursor lesion that is allocated to a more aggressive,"

The WHO review assigns dVIN to the more aggressive HPV-independent keratinizing squamous carcinoma precursor pathway.

DOI:10.1055/a-1545-4279 SUPPORT Human Clinical

"Less common form of VIN No spontaneous regression Older women Faster rate of progression VIN squamous cell carcinoma"

The WHO clinicopathologic figure supports the qualitative natural-history differences used here without assigning an unsupported numerical risk.

DOI:10.3390/diagnostics14161799 SUPPORT Human Clinical

"The histopathologic features, degree of differentiation, and associations with lichen planus, lichen sclerosus, and HPV guide the selection of conservative treatments or surgical excision."

In this VIN-focused review, lichen sclerosus and HPV are explicit contexts used with differentiation to classify and manage vulvar precursor lesions.

HPV-Independent Somatic Driver Accumulation

HPV-independent VSCC is enriched for TERT promoter, TP53, CDKN2A, NOTCH1, and FAT1 alterations, supporting a tumor-suppressor and differentiation failure pathway distinct from HPV-driven tumors.

vulvar keratinocyte CL:0000312

TP53 hgnc:11998 TERT hgnc:11730 CDKN2A hgnc:1787 NOTCH1 hgnc:7881 FAT1 hgnc:3595

apoptotic process GO:0006915 ↓ DECREASED cell population proliferation GO:0008283 ↑ INCREASED

Downstream

Differentiated Vulvar Intraepithelial Neoplasia (dVIN) Early HPV-independent somatic drivers can be selected within the differentiated precursor pathway.

Clonal Squamous Cell Proliferation Somatic driver alterations support malignant clonal expansion in vulvar keratinocytes.

Show evidence (2 references)

PMID:34650187 SUPPORT Human Clinical

"Other common abnormalities in HPV-independent tumors were TP53 mutations (13/15, 87%), CDKN2A alterations (10/15, 67%), and NOTCH1 and FAT1 mutations (7/15, 47% each)."

Sequencing of vulvovaginal squamous carcinomas identifies recurrent TP53, CDKN2A, NOTCH1, and FAT1 alterations in HPV-independent tumors.

PMID:34650187 SUPPORT Human Clinical

"Cancer cell fraction analysis of HPV-independent squamous carcinomas suggests that TERT and/or NOTCH1 alterations along with TP53 alterations can be the initiating event in these tumors."

The paper places TERT, NOTCH1, and TP53 alterations early in the HPV-independent carcinogenic pathway.

PIK3CA-Activated HPV-Associated Signaling

HPV-associated vulvovaginal squamous carcinomas are enriched for PIK3CA activating mutations, implicating PI3K pathway activation in a subset of HPV-driven tumors.

PIK3CA hgnc:8975

cell population proliferation GO:0008283 ↑ INCREASED

Downstream

Clonal Squamous Cell Proliferation PI3K pathway activation supports tumor cell growth and survival.

Show evidence (1 reference)

PMID:34650187 SUPPORT Human Clinical

"HPV-associated vulvovaginal squamous cell carcinoma had PIK3CA activating mutations (7/11, 64%) as the most common genomic event"

This sequencing cohort supports PIK3CA activation as a recurrent event in HPV-associated vulvovaginal squamous carcinoma.

HRAS/RAS-MAPK Signaling Activation

HRAS mutations occur in a subset of VSCC and implicate RAS/MAPK signaling as an additional proliferation pathway in vulvar squamous carcinoma.

HRAS hgnc:5173

MAPK cascade GO:0000165 ↑ INCREASED cell population proliferation GO:0008283 ↑ INCREASED

Downstream

Clonal Squamous Cell Proliferation HRAS-driven MAPK signaling can promote transformed keratinocyte proliferation.

Show evidence (1 reference)

DOI:10.1038/s41598-024-63913-z SUPPORT Human Clinical

"Somatic mutations were identified by targeted or panel sequencing, and TP53 was identified as the most common mutation (52–81%), followed by HRAS (7–26%), CDKN2A (21–24%), and PIK3CA (5–10%)."

The Japanese VSCC sequencing cohort identifies recurrent HRAS mutations, supporting a RAS/MAPK-linked somatic driver mechanism.

Clonal Squamous Cell Proliferation

HPV-driven cell-cycle deregulation or HPV-independent somatic driver accumulation leads to clonal proliferation and invasive squamous carcinoma in the vulvar epithelium.

vulvar keratinocyte CL:0000312

cell population proliferation GO:0008283 ↑ INCREASED

vulva UBERON:0000997

Downstream

Squamous Cell Carcinoma Malignant clonal expansion produces invasive squamous carcinoma histology.

Squamous Cell Carcinoma

Invasive squamous carcinoma is the dominant malignant histology of vulvar carcinoma and produces the local lesion phenotypes through tumor growth and tissue destruction.

vulvar squamous carcinoma cell CL:0000312

vulva UBERON:0000997

Downstream

Biopsy-Requiring Vulvar Lesion Invasive growth produces a persistent or suspicious lesion requiring biopsy.

Vulvar Lump or Mass Expanding tumor can present clinically as a vulvar lump or mass.

Vulvar Ulcer Local tumor growth and tissue destruction can present as ulceration.

Vulvar Pruritus Vulvar squamous carcinoma commonly presents with vulvar pruritus.

Vulvar Pain or Soreness Vulvar squamous carcinoma commonly presents with vulvar pain.

Inguinofemoral Nodal Metastasis Invasive vulvar squamous carcinoma can spread to inguinofemoral lymph nodes.

Fibroblast-Supported Tumor Invasion Established tumor cells interact with cancer-associated fibroblasts during invasion.

Show evidence (1 reference)

PMID:38791925 SUPPORT Human Clinical

"Vulvar squamous cell carcinoma (VSCC) is the most common type."

The clinical review identifies VSCC as the predominant histologic type of vulvar carcinoma.

Inguinofemoral Nodal Metastasis

Regional spread to inguinofemoral lymph nodes is a major adverse prognostic event in vulvar cancer and defines the target of groin-directed treatment.

inguinal lymph node UBERON:0001542

Show evidence (2 references)

DOI:10.3389/or.2024.1389035 SUPPORT Human Clinical

"Nodal involvement and surgical margin status are the two most important prognostic factors for local and distant recurrence, representing the two main factors analyzed for recommending adjuvant therapy."

The systematic review identifies nodal involvement as a principal prognostic factor and treatment-decision context.

DOI:10.3389/or.2024.1389035 SUPPORT Human Clinical

"in women with resectable disease without nodal involvement, the 5-year OS rate is more than 80%, while it falls dramatically to less than 40% in women with inguinal nodal involvement"

This directly supports the adverse prognostic significance of inguinal nodal involvement without extrapolating to an individual prognosis.

Fibroblast-Supported Tumor Invasion

Cancer-associated fibroblasts support invasion and tumor formation by a lichen-sclerosus-associated VSCC cell line in organotypic culture and xenograft models, implicating stromal support in local progression.

cancer-associated fibroblast CL:0000057 vulvar squamous carcinoma cell CL:0000312

cell migration GO:0016477 ↑ INCREASED

Experimental models

VCC1 Lichen-Sclerosus-Associated VSCC Cell Line CELL LINE Tests whether cancer-associated fibroblasts support VSCC invasion and tumor formation.

Show evidence (2 references)

PMID:31654625 SUPPORT In Vitro

"In vitro 3D organotypic assays and in vivo xenografts revealed a prominent role of cancer-associated fibroblasts in VCC1 invasion and tumor formation."

The in vitro component of the reported combined result supports fibroblast-dependent invasion in 3D organotypic assays.

PMID:31654625 SUPPORT Model Organism

"In vitro 3D organotypic assays and in vivo xenografts revealed a prominent role of cancer-associated fibroblasts in VCC1 invasion and tumor formation."

The in vivo xenograft component independently supports fibroblast-dependent tumor formation in a model-organism context.

✶

Histopathology

3

HPV-Associated High-Grade Squamous Intraepithelial Lesion (HSIL/uVIN)

HPV-associated vulvar HSIL corresponds to usual-type VIN 2/3. Histopathology is the diagnostic standard, and p16 expression is used as a surrogate of HPV association.

Show evidence (2 references)

DOI:10.1055/a-1545-4279 SUPPORT Human Clinical

"Immunohistochemical p16 expression is considered to be a surrogate marker for HPV association."

The WHO review supports p16 expression as a surrogate marker of the HPV-associated precursor pathway.

PMID:39202286 SUPPORT Human Clinical

"Histopathological examination represents the gold-standard diagnosis in VIN and PeIN, while p16 and p53 immunostainings alongside HPV testing provide crucial diagnostic clues."

This supports histopathology as the VIN diagnostic standard and molecular testing as classification evidence rather than as a substitute for biopsy.

Differentiated Vulvar Intraepithelial Neoplasia (dVIN)

dVIN is an HPV-independent precursor commonly associated with lichen sclerosus, aberrant p53 expression, and the keratinizing VSCC pathway.

Show evidence (2 references)

DOI:10.1055/a-1545-4279 SUPPORT Human Clinical

"HPV-independent VIN (d-VIN), e and f keratinizing squamous cell carcinoma of the vulva with a netlike pattern of invasion and aberrant p53 expression (see text)."

The WHO figure caption directly supports the dVIN, aberrant-p53, and keratinizing carcinoma association.

PMID:39202286 SUPPORT Human Clinical

"Histopathological examination represents the gold-standard diagnosis in VIN and PeIN, while p16 and p53 immunostainings alongside HPV testing provide crucial diagnostic clues."

This supports histopathology plus p53/p16/HPV evidence for distinguishing differentiated HPV-independent VIN from HPV-associated HSIL.

Squamous Cell Carcinoma

Vulvar squamous cell carcinoma is the most common histologic type of vulvar carcinoma.

Show evidence (1 reference)

PMID:38791925 SUPPORT Human Clinical

"Vulvar squamous cell carcinoma (VSCC) is the most common type."

This review supports squamous cell carcinoma as the dominant vulvar carcinoma histology.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

5

Integument 2

Biopsy-Requiring Vulvar Lesion Localized skin lesion HP:0011355

Show evidence (1 reference)

PMID:38791925 SUPPORT Human Clinical

"Diagnosis relies on biopsy during vulvoscopy, plus imaging such as ultrasonography (USG), magnetic resonance imaging (MRI) and positron emission tomography (PET)."

The need for vulvoscopy-directed biopsy supports a visible or clinically suspicious vulvar lesion as the diagnostic presentation.

Vulvar Ulcer Skin ulcer HP:0200042

Show evidence (1 reference)

DOI:10.1002/ijgo.13881 SUPPORT Human Clinical

"While vulvar cancer may be asymptomatic, most women present with vulvar pruritus or pain, or have noticed a lump or ulcer."

The clinical update identifies ulcer as a presenting feature; the HPO binding uses the broader skin-ulcer term because local HPO did not provide a vulvar-specific ulcer term.

Other 3

Vulvar Lump or Mass Vulvar neoplasm HP:0030416

Show evidence (1 reference)

DOI:10.1002/ijgo.13881 SUPPORT Human Clinical

"While vulvar cancer may be asymptomatic, most women present with vulvar pruritus or pain, or have noticed a lump or ulcer."

The clinical update identifies a noticed lump as a presenting feature of vulvar cancer, represented by the vulvar-specific HPO neoplasm term.

Vulvar Pruritus Pruritus vulvae HP:0032004

Show evidence (2 references)

DOI:10.1002/ijgo.13881 SUPPORT Human Clinical

"While vulvar cancer may be asymptomatic, most women present with vulvar pruritus or pain, or have noticed a lump or ulcer."

The disease-specific clinical review directly supports vulvar pruritus as a presenting symptom of vulvar cancer.

DOI:10.3389/fmed.2023.1106318 SUPPORT Human Clinical

"The typical clinical picture includes chronic whitish atrophic patches along with itching and soreness in the vulvar, perianal and penile regions."

This supports pruritus in lichen sclerosus, an important associated precursor/risk setting for HPV-independent vulvar carcinoma.

Vulvar Pain or Soreness Vulvodynia HP:0030943

Show evidence (2 references)

DOI:10.1002/ijgo.13881 SUPPORT Human Clinical

"While vulvar cancer may be asymptomatic, most women present with vulvar pruritus or pain, or have noticed a lump or ulcer."

The disease-specific clinical review directly supports vulvar pain as a presenting symptom of vulvar cancer.

DOI:10.3389/fmed.2023.1106318 SUPPORT Human Clinical

"The typical clinical picture includes chronic whitish atrophic patches along with itching and soreness in the vulvar, perianal and penile regions."

This supports vulvar soreness in lichen sclerosus, a clinically relevant associated dermatosis in the HPV-independent disease pathway.

🧬

Genetic Associations

7

TP53 (Somatic Mutation)

Gene: TP53 hgnc:11998

Show evidence (1 reference)

PMID:37840151 SUPPORT Human Clinical

"The TP53 mutation status was identified as an independent prognostic factor of worse progression-free survival (p = 0.024) after adjustment for FIGO stage."

This cohort supports TP53 mutation as a prognostic somatic alteration in VSCC.

PIK3CA (Somatic Activating Mutation)

Gene: PIK3CA hgnc:8975

Show evidence (1 reference)

PMID:34650187 SUPPORT Human Clinical

"HPV-associated vulvovaginal squamous cell carcinoma had PIK3CA activating mutations (7/11, 64%) as the most common genomic event"

This supports PIK3CA activation as a recurrent molecular event in the HPV-associated pathway.

TERT (Somatic Promoter Alteration)

Gene: TERT hgnc:11730

Show evidence (1 reference)

PMID:34650187 SUPPORT Human Clinical

"TERT gene alterations, mainly TERT promoter mutations (14/15 cases, 93%) featured significantly in HPV-independent carcinomas."

This supports TERT promoter alteration as a frequent HPV-independent VSCC driver event.

CDKN2A (Somatic Alteration)

Gene: CDKN2A hgnc:1787

Show evidence (1 reference)

PMID:34650187 SUPPORT Human Clinical

"Other common abnormalities in HPV-independent tumors were TP53 mutations (13/15, 87%), CDKN2A alterations (10/15, 67%), and NOTCH1 and FAT1 mutations (7/15, 47% each)."

This supports CDKN2A alteration as a recurrent somatic event in the HPV-independent molecular subgroup.

NOTCH1 (Somatic Mutation)

Gene: NOTCH1 hgnc:7881

Show evidence (1 reference)

PMID:34650187 SUPPORT Human Clinical

"Other common abnormalities in HPV-independent tumors were TP53 mutations (13/15, 87%), CDKN2A alterations (10/15, 67%), and NOTCH1 and FAT1 mutations (7/15, 47% each)."

This supports NOTCH1 mutation as a recurrent somatic event in HPV-independent vulvovaginal squamous carcinoma.

FAT1 (Somatic Mutation)

Gene: FAT1 hgnc:3595

Show evidence (1 reference)

PMID:34650187 SUPPORT Human Clinical

"Other common abnormalities in HPV-independent tumors were TP53 mutations (13/15, 87%), CDKN2A alterations (10/15, 67%), and NOTCH1 and FAT1 mutations (7/15, 47% each)."

This supports FAT1 mutation as a recurrent somatic event in HPV-independent vulvovaginal squamous carcinoma.

HRAS (Somatic Mutation)

Gene: HRAS hgnc:5173

Show evidence (1 reference)

DOI:10.1038/s41598-024-63913-z SUPPORT Human Clinical

"Somatic mutations were identified by targeted or panel sequencing, and TP53 was identified as the most common mutation (52–81%), followed by HRAS (7–26%), CDKN2A (21–24%), and PIK3CA (5–10%)."

This supports HRAS as a recurrent somatic mutation in Japanese VSCC sequencing cohorts.

💊

Medical Actions

7

Local Excision With Sentinel Node Biopsy

Action: surgical procedure Ontology label: Surgical Procedure NCIT:C15329

Early-stage vulvar cancer is treated by local excision of the primary tumor with sentinel node biopsy when nodal assessment is indicated, reducing morbidity compared with inguinofemoral lymphadenectomy in appropriate patients.

Mechanism Target:

INHIBITS Squamous Cell Carcinoma — Local excision removes the invasive primary tumor.

Show evidence (1 reference)

DOI:10.6004/jnccn.2024.7002 SUPPORT Human Clinical

"Early-stage vulvar cancer is managed by a local excision of the primary tumor and, if indicated, a sentinel node (SN) biopsy to assess the need for further groin treatment."

This review supports local excision and sentinel node biopsy as standard early-stage management.

Inguinofemoral Radiotherapy for Sentinel-Node Micrometastases

Action: radiation therapy Ontology label: Radiation Therapy NCIT:C15313

In patients with sentinel-node micrometastases, inguinofemoral radiotherapy is a groin-treatment alternative to inguinofemoral lymphadenectomy with comparable efficacy and lower treatment-related morbidity. This evidence does not support a blanket definitive or adjuvant radiotherapy claim.

Mechanism Target:

INHIBITS Inguinofemoral Nodal Metastasis — Groin-directed radiotherapy controls micrometastatic inguinofemoral nodal disease.

Show evidence (1 reference)

DOI:10.6004/jnccn.2024.7002 SUPPORT Human Clinical

"Inguinofemoral radiotherapy is a good alternative to IFL in patients with micrometastases in the SN, with comparable efficacy and less treatment-related morbidity."

The sentinel-node review supports only the selected micrometastatic sentinel-node context curated here.

Adjuvant Radiotherapy for Resected Node-Positive Disease

Action: radiation therapy Ontology label: Radiation Therapy NCIT:C15313

After surgery for inguinofemoral node-positive vulvar cancer, adjuvant radiotherapy may reduce groin recurrence. The systematic-review evidence is explicitly very low certainty, so this entry does not claim a definitive overall-survival benefit or universal indication.

Mechanism Target:

INHIBITS Inguinofemoral Nodal Metastasis — Adjuvant groin radiotherapy aims to control residual regional nodal disease after surgery.

Show evidence (2 references)

DOI:10.3389/or.2024.1389035 SUPPORT Human Clinical

"Three (5.3%) versus 13 (24.1%) groin recurrences were noted, respectively, in the adjuvant radiotherapy and pelvic lymphadenectomy groups."

The single eligible randomized trial reported fewer groin recurrences after adjuvant radiotherapy than after pelvic lymphadenectomy.

DOI:10.3389/or.2024.1389035 SUPPORT Human Clinical

"There is only very low-quality evidence on administering adjuvant radiotherapy for inguinal lymph node metastases."

The review's certainty statement limits this treatment claim and prevents extrapolation to broad definitive or routine adjuvant radiotherapy.

Concurrent Chemoradiotherapy for Advanced Tumors

Action: chemoradiotherapy Ontology label: Chemoradiotherapy NCIT:C94626

Concurrent chemoradiotherapy is an effective alternative to surgery for advanced vulvar tumors, particularly when curative resection would be infeasible or excessively morbid.

Mechanism Target:

INHIBITS Squamous Cell Carcinoma — Concurrent chemoradiotherapy provides local tumor control in selected advanced VSCC.

Show evidence (1 reference)

PMID:34669204 SUPPORT Human Clinical

"Treatment is predominantly surgical, particularly for squamous cell carcinoma, although concurrent chemoradiation is an effective alternative, particularly for advanced tumors."

The clinical update directly supports concurrent chemoradiation as an alternative for advanced vulvar tumors.

First-Line Platinum-Based Chemotherapy Context in Advanced or Recurrent VSCC

Action: chemotherapy Ontology label: Chemotherapy NCIT:C15632

Agent: platinum compound NCIT:C1450

An ongoing maintenance trial enrolls patients after four to six cycles of first-line platinum-based chemotherapy for advanced or recurrent VSCC not amenable to curative surgery. This establishes a trial-treatment context, not comparative efficacy or a universal standard-of-care recommendation.

Mechanism Target:

INHIBITS Squamous Cell Carcinoma — Platinum-based cytotoxic chemotherapy is directed at advanced or recurrent VSCC tumor burden in this trial context.

Show evidence (1 reference)

clinicaltrials:NCT07101848 SUPPORT Human Clinical

"This is a phase II, randomized study that will include 42 participants who have received 4 to 6 cycles of first-line platinum-based chemotherapy for advanced vulvar squamous cell carcinoma (SCC) not amenable to curative surgical treatment (FIGO 2018 stages III-IV - International Federation of..."

The trial summary explicitly requires prior first-line platinum-based chemotherapy and therefore supports only the calibrated context stated here.

HPV Vaccination

Action: vaccination Ontology label: Vaccination NCIT:C15346

Agent: human papillomavirus vaccine NCIT:C1951

Prophylactic HPV vaccination is a prevention strategy intended to reduce the future burden of HPV-related cancers, including HPV-associated vulvar cancer.

Mechanism Target:

INHIBITS High-Risk HPV Infection — Prophylactic vaccination prevents acquisition and transmission of vaccine-type high-risk HPV infection upstream of HPV-associated VSCC.

Show evidence (2 references)

DOI:10.3390/vaccines12111291 SUPPORT Human Clinical

"Vaccination against HPV can effectively block the transmission of the virus and prevent HPV-related cancers."

The vaccine review directly supports prophylactic HPV vaccination as prevention of HPV infection transmission and HPV-related cancers, explicitly including vulvar cancer in its scope.

DOI:10.1001/jamanetworkopen.2024.31807 SUPPORT Human Clinical

"Designing and implementing targeted interventions to increase uptake and completion of HPV vaccination series across counties with low HPV vaccination rates may help to reduce future the burden of HPV-related cancers."

This population-based study supports HPV vaccination uptake as a strategy to reduce future HPV-related cancer burden, which includes HPV-associated vulvar carcinoma.

Lichen Sclerosus Maintenance Therapy and Lifelong Surveillance

Action: topical corticosteroid therapy Ontology label: Topical Corticosteroid Therapy NCIT:C122078

In vulvar lichen sclerosus, regular topical corticosteroid maintenance and long-term follow-up support symptom control, detection of premalignant lesions, and risk management in the HPV-independent pathway. This is prevention and surveillance of a risk condition, not treatment of invasive VSCC.

Mechanism Target:

MODULATES Lichen Sclerosus Inflammatory Microenvironment — Maintenance therapy and surveillance manage the inflammatory dermatosis and its long-term malignant-risk context.

Show evidence (2 references)

DOI:10.3389/fmed.2023.1106318 SUPPORT Human Clinical

"early detection of premalignant lesions and a lifelong follow-up are required"

The review directly supports lifelong follow-up for the vulvar lichen sclerosus cancer-risk context.

DOI:10.3389/fmed.2023.1106318 SUPPORT Human Clinical

"one study shows a statistically significant lesser likelihood to develop malignancies when TC were regularly used as a prophylactic measure in asymptomatic VLS"

This supports regular topical-corticosteroid maintenance as a risk-reducing association in VLS without claiming randomized proof of cancer prevention.

🌍

Environmental Factors

1

Cigarette Smoking Exposure

Cigarette smoking is an epidemiologic risk factor for vulvar cancer. The evidence supports a predisposing association, while the intermediate vulvar-carcinogenesis mechanism remains unspecified.

Show evidence (1 reference)

PMID:38503056 SUPPORT Other

"Known risk factors for vulvar cancer include increasing age, infection with human papillomavirus, cigarette smoking, inflammatory conditions affecting the vulva, and immunodeficiency."

The NCCN guideline summary directly supports cigarette smoking as an epidemiologic risk factor for vulvar cancer.

Mechanism Target:

PREDISPOSES Squamous Cell Carcinoma — Smoking increases vulvar-cancer risk through incompletely resolved intermediates and is therefore modeled as predisposing rather than as a direct tumor-triggering event.

Show evidence (1 reference)

PMID:38503056 SUPPORT Other

"Known risk factors for vulvar cancer include increasing age, infection with human papillomavirus, cigarette smoking, inflammatory conditions affecting the vulva, and immunodeficiency."

The guideline lists cigarette smoking as a vulvar-cancer risk factor but does not establish a direct molecular route, supporting this calibrated edge.

🔬

Biochemical Markers

2

p16 Immunohistochemistry

Pathograph Readouts

Readout Of High-Risk HPV Infection Positive Diagnostic

Block-type p16 staining is a reliable but imperfect surrogate readout of HPV association and does not itself identify an HPV genotype.

Show evidence (1 reference)

DOI:10.1055/a-1545-4279 SUPPORT Human Clinical

"Immunohistochemical p16 expression is considered to be a surrogate marker for HPV association."

The WHO review directly supports p16 expression as a surrogate readout of HPV association.

Show evidence (1 reference)

PMID:37840151 SUPPORT Human Clinical

"Immunohistochemistry for p53, Ki67 and p16INK4A (a surrogate marker for HPV infection) was performed on formalin-fixed paraffin-embedded tissues from a cohort of surgically treated VSCC patients to identify molecular subtypes of VSCC."

The study supports p16INK4A immunohistochemistry as an HPV-associated subtype marker in VSCC.

p53 Immunohistochemistry

Pathograph Readouts

Correlates With HPV-Independent Somatic Driver Accumulation Positive Diagnostic

An aberrant p53 staining pattern supports the TP53-altered HPV-independent pathway but is not represented as a direct sequencing measurement of every somatic driver in this node.

Show evidence (1 reference)

DOI:10.1055/a-1545-4279 SUPPORT Human Clinical

"Analysis using p53 immunohistochemistry may help to more accurately diagnose VIN and vulvar squamous cell carcinoma"

The WHO review supports p53 immunohistochemistry as a diagnostic correlate rather than a direct mutation assay.

Show evidence (1 reference)

PMID:37840151 SUPPORT Human Clinical

"The results of p53 and p16INK4A immunohistochemistry confirmed three VSCC subtypes associated with different prognosis."

This supports combined p53 and p16 immunohistochemistry for molecular stratification of VSCC.

🔬

Diagnosis

3

Biopsy of a Suspicious Vulvar Lesion

A persistent or suspicious vulvar lesion requires biopsy to exclude invasion and establish histologic diagnosis.

biopsy procedure NCIT:C15189

Results: Histopathologic confirmation or exclusion of invasive vulvar carcinoma.

Show evidence (1 reference)

PMID:34669204 SUPPORT Human Clinical

"Therefore, any suspicious vulvar lesion should be biopsied to exclude invasion."

The clinical update directly supports biopsy of suspicious vulvar lesions to determine whether invasion is present.

Preoperative Imaging for Local, Nodal, and Distant Disease

Imaging complements clinical assessment for staging, with modality choice tailored to local extension, groin nodes, and suspected distant metastasis.

imaging procedure NCIT:C17369

Results: Extent of primary, nodal, and distant vulvar cancer involvement.

Show evidence (2 references)

PMID:38927973 SUPPORT Human Clinical

"Various imaging modalities are widely used in conjunction with clinical assessment in the diagnosis and staging of vulval cancers; however, there is significant heterogeneity in which modalities are recommended in international guidelines, reflecting the paucity of evidence in this area."

The imaging review supports imaging as an adjunct to clinical diagnosis and staging while preserving uncertainty about the optimal modality.

PMID:38927973 SUPPORT Human Clinical

"For distant metastases, CT CAP and FDG-PET/CT have the most evidence to support their use."

This supports CT chest/abdomen/pelvis and FDG-PET/CT when distant metastatic assessment is required.

p16 and p53 Immunohistochemical Subtyping With Selective HPV Testing

Histopathology with p16 and p53 immunostaining supports assignment of HPV-associated, HPV-independent p53-abnormal, and HPV-independent p53-wild-type VSCC. HPV DNA PCR or HPV mRNA in situ hybridization can document or resolve HPV status in selected cases; this entry does not claim that direct HPV testing is universally required for every tumor.

immunohistochemistry NCIT:C23020

Results: Assignment of a prognostically meaningful VSCC molecular subtype.

Show evidence (3 references)

DOI:10.3390/cancers16244216 SUPPORT Human Clinical

"The molecular subtyping of VSCC shows high reproducibility and provides important prognostic information."

The review supports molecular subtyping as reproducible and prognostically informative without relying on its grammatically ambiguous diagnostic sentence.

PMID:37840151 SUPPORT Human Clinical

"Immunohistochemistry for p53, Ki67 and p16INK4A (a surrogate marker for HPV infection) was performed on formalin-fixed paraffin-embedded tissues from a cohort of surgically treated VSCC patients to identify molecular subtypes of VSCC. Presence of HPV infection was detected by HPV DNA PCR and HPV..."

This cohort demonstrates a practical workflow using p16/p53 immunohistochemistry plus direct HPV DNA/RNA assays to establish subtype.

DOI:10.3390/diagnostics14161799 SUPPORT Human Clinical

"Histopathological examination represents the gold-standard diagnosis in VIN and PeIN, while p16 and p53 immunostainings alongside HPV testing provide crucial diagnostic clues."

The review frames p16, p53, and HPV testing as diagnostic clues alongside histopathology, supporting calibrated rather than universally mandatory wording.

📈

Progression

3

HPV-associated HSIL/uVIN precursor lesion to invasive carcinoma

HPV-associated VIN 2/3 corresponds to HSIL. Its progression toward squamous carcinoma is generally slower than dVIN, and spontaneous regression can occur within the HPV-associated VIN spectrum, especially in lower-grade VIN.

Show evidence (1 reference)

DOI:10.1055/a-1545-4279 SUPPORT Human Clinical

"Spontaneous regression possible (especially VIN 1) Most common form of VIN Slower rate of progression squamous cell carcinomaVIN"

The WHO review supplies a qualitative, subtype-specific natural-history comparison; no unsupported numerical transition probability is inferred.

Differentiated VIN precursor lesion to invasive carcinoma

dVIN is less common, occurs in older women, can accompany lichen sclerosus, has no expected spontaneous regression, and progresses more rapidly toward squamous carcinoma than HPV-associated VIN.

Show evidence (2 references)

DOI:10.1055/a-1545-4279 SUPPORT Human Clinical

"Less common form of VIN No spontaneous regression Older women Faster rate of progression VIN squamous cell carcinoma"

This directly supports the calibrated qualitative natural history of dVIN.

DOI:10.3390/diagnostics14161799 SUPPORT Human Clinical

"The histopathologic features, degree of differentiation, and associations with lichen planus, lichen sclerosus, and HPV guide the selection of conservative treatments or surgical excision."

The VIN-focused review supports lichen sclerosus as a precursor-lesion context; the progression-rate comparison remains sourced to WHO.

Vulvar lichen sclerosus-associated risk surveillance

Vulvar lichen sclerosus carries a long-term vulvar-cancer risk that rises over extended follow-up, supporting early detection of premalignant lesions and lifelong surveillance rather than a fixed short surveillance window.

Show evidence (1 reference)

DOI:10.3389/fmed.2023.1106318 SUPPORT Human Clinical

"the cumulative probability of progression to vulvar cancer escalates from 1.2% at 2 years to 36.8% at 25 years"

The review reports increasing long-term cumulative progression in a VLS cohort and supports sustained surveillance in this specific risk context.

🪜

Stages

1

FIGO 2021 Vulvar Carcinoma Staging

The data-derived 2021 FIGO system stages vulvar carcinoma across Stages I through IV, incorporates tumor, nodal, and distant-disease characteristics, and permits cross-sectional imaging findings to contribute to staging.

Show evidence (2 references)

PMID:34520062 SUPPORT Human Clinical

"The resulting new staging for carcinoma of the vulva has two substages in Stage I, no substage in Stage II, three substages in Stage III, and two substages in Stage IV."

The FIGO revision defines the current stage and substage structure from a 12,063-case dataset.

PMID:34520062 SUPPORT Human Clinical

"This revision has a new definition for depth of invasion, uses the same definition for lymph node metastases utilized in cervical cancer, and allows findings from cross-sectional imaging to be incorporated into vulvar cancer staging."

This directly supports the invasion-depth, nodal, and imaging components of the 2021 FIGO staging framework.

📊

Prevalence

1

Global, 2022

The cited review also reports approximately 47,000 global cases in 2022. This record is a proportional disease-burden context, not a point-prevalence estimate or population incidence rate.

Show evidence (1 reference)

PMID:38927973 SUPPORT Human Clinical

"Vulval cancer is a rare gynaecological cancer, accounting for 3% of all gynaecological malignancies, with 47,000 cases in 2022 globally."

The review supplies a scope-safe global case count and proportion among gynecologic malignancies without implying a population prevalence rate.

🦠

Infectious Agent

1

High-Risk Human Papillomavirus

High-risk HPV infection drives the HPV-associated pathway of vulvar squamous cell carcinoma through viral oncogene effects and is commonly assessed by p16 immunohistochemistry or HPV RNA/DNA testing.

human papillomavirus NCBITaxon:10566

Show evidence (1 reference)

PMID:37840151 SUPPORT Human Clinical

"Immunohistochemistry for p53, Ki67 and p16INK4A (a surrogate marker for HPV infection) was performed on formalin-fixed paraffin-embedded tissues from a cohort of surgically treated VSCC patients to identify molecular subtypes of VSCC. Presence of HPV infection was detected by HPV DNA PCR and HPV..."

This cohort operationalizes HPV-associated VSCC using p16, HPV DNA PCR, and HPV mRNA ISH, supporting high-risk HPV as the infectious driver in this molecular subtype.

🔬

Clinical Trials

3

NCT05903833 PHASE_II RECRUITING

Phase II trial of pembrolizumab plus lenvatinib in recurrent, persistent, metastatic, or locally advanced vulvar cancer not amenable to curative surgery or radiotherapy. ClinicalTrials.gov listed status as RECRUITING on 2026-08-08.

Target Phenotypes: Recurrent, persistent, metastatic, or locally advanced vulvar cancer

Show evidence (1 reference)

clinicaltrials:NCT05903833 SUPPORT

"Evaluation of efficacy and safety of pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulva cancer."

This ClinicalTrials.gov summary directly describes the study population and pembrolizumab-lenvatinib intervention.

NCT07101848 PHASE_II NOT_RECRUITING

Phase II randomized trial of cemiplimab maintenance plus best supportive care versus best supportive care after first-line platinum chemotherapy in advanced or recurrent vulvar squamous cell carcinoma. ClinicalTrials.gov listed status as NOT_YET_RECRUITING on 2026-08-08, represented here by the schema's NOT_RECRUITING status enum.

Target Phenotypes: Advanced or recurrent vulvar squamous cell carcinoma

Show evidence (1 reference)

clinicaltrials:NCT07101848 SUPPORT

"This is a phase II, randomized study that will include 42 participants who have received 4 to 6 cycles of first-line platinum-based chemotherapy for advanced vulvar squamous cell carcinoma (SCC) not amenable to curative surgical treatment (FIGO 2018 stages III-IV - International Federation of..."

This ClinicalTrials.gov summary supports the trial design and population for cemiplimab maintenance in advanced or recurrent VSCC.

NCT07290894 PHASE_II RECRUITING

Phase II single-arm, multi-cohort trial of lenvatinib plus pembrolizumab in patients with vulvar cancer. ClinicalTrials.gov listed status as RECRUITING on 2026-08-08.

Target Phenotypes: Vulvar cancer

Show evidence (1 reference)

clinicaltrials:NCT07290894 SUPPORT

"MITO VULVA-1 is a prospective, single arm, multi-cohorts, phase II trial that aims to assess the activity and the safety of Lenvatinib plus Pembrolizumab in patients with vulvar cancer."

This ClinicalTrials.gov summary directly supports the MITO VULVA-01 trial and intervention for patients with vulvar cancer.

🧫

Experimental Models

1

VCC1 Lichen-Sclerosus-Associated VSCC Cell Line CELL_LINE

VCC1 is a spontaneously immortalized human vulvar squamous carcinoma cell line derived from lichen-sclerosus-associated VSCC. Three-dimensional organotypic cultures and xenografts make it useful for studying tumor-stroma dependence, invasion, and drug response.

Organism

human NCBITaxon:9606

Tissue

vulva UBERON:0000997

Cell source

Spontaneously immortalized VCC1 cells isolated from a human lichen-sclerosus-associated VSCC.

Culture

Monolayer culture and three-dimensional fibroblast-containing organotypic culture, complemented by xenografts.

Publication

PMID:31654625

Pathograph links

Fibroblast-Supported Tumor Invasion Tests whether cancer-associated fibroblasts support VSCC invasion and tumor formation.

Show evidence (2 references)

PMID:31654625 SUPPORT In Vitro

"In vitro 3D organotypic assays and in vivo xenografts revealed a prominent role of cancer-associated fibroblasts in VCC1 invasion and tumor formation."

The organotypic arm links this in vitro model to fibroblast-supported VCC1 invasion.

+ 1 more reference

Findings

VCC1 retains epithelial morphology and well-differentiated keratinizing squamous carcinoma histology resembling the source tumor.

"Detailed characterization of the novel spontaneously immortalized cell line, VCC1 revealed a characteristic epithelial morphology in vitro and a well-differentiated keratinizing SCC histology in vivo, closely resembling the tumor of origin."

VCC1 shows increased epithelial-mesenchymal-transition markers and clonogenic properties relative to established non-VLS-VSCC lines.

"VCC1 expressed higher levels of epithelial-mesenchymal transition markers and higher clonogenic properties as compared to other established non VLS-VSCC cell lines."

Show evidence (2 references)

PMID:31654625 SUPPORT In Vitro

"In vitro 3D organotypic assays and in vivo xenografts revealed a prominent role of cancer-associated fibroblasts in VCC1 invasion and tumor formation."

The in vitro organotypic component supports VCC1 as a model of fibroblast-dependent invasion.

PMID:31654625 SUPPORT Model Organism

"In vitro 3D organotypic assays and in vivo xenografts revealed a prominent role of cancer-associated fibroblasts in VCC1 invasion and tumor formation."

The in vivo xenograft component supports VCC1 as a model of fibroblast-dependent tumor formation.

{ }

Source YAML

click to show

name: Vulvar Carcinoma
creation_date: "2026-05-07T18:59:34Z"
synonyms:
- Vulvar cancer
- Carcinoma of the vulva
- Vulvar squamous cell carcinoma
- VSCC
description: >-
  Vulvar carcinoma is a rare epithelial malignancy of the vulva. Vulvar
  squamous cell carcinoma is the dominant histologic subtype, and current
  molecular classification separates HPV-associated tumors from
  HPV-independent tumors, the latter often involving TP53 pathway disruption
  and chronic vulvar dermatoses such as lichen sclerosus.
categories:
- Gynecologic Malignancy
- Solid Tumor
- HPV-Related Cancer
parents:
- vulva cancer
disease_term:
  preferred_term: vulvar carcinoma
  term:
    id: MONDO:0005215
    label: vulvar carcinoma
definitions:
- name: Clinicopathologic definition
  definition_type: CASE_DEFINITION
  description: >-
    Vulvar carcinoma is a vulvar epithelial cancer, most commonly squamous
    cell carcinoma, diagnosed by biopsy of a suspicious vulvar lesion and
    staged with clinical, pathologic, and imaging assessment of local and
    nodal disease.
  scope: General adult gynecologic oncology definition
  evidence:
  - reference: PMID:38791925
    reference_title: "Current Preoperative Management of Vulvar Squamous Cell Carcinoma: An Overview."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Vulvar carcinoma is a rare cancer affecting the genital tract,
      constituting 4% of gynecological tumors. Vulvar squamous cell carcinoma
      (VSCC) is the most common type. Diagnosis relies on biopsy during
      vulvoscopy, plus imaging such as ultrasonography (USG), magnetic
      resonance imaging (MRI) and positron emission tomography (PET).
    explanation: >-
      This review defines vulvar carcinoma as a rare gynecologic cancer,
      identifies VSCC as the most common type, and summarizes biopsy and
      imaging-based preoperative assessment.
  - reference: DOI:10.1055/a-1545-4279
    reference_title: "2020 WHO Classification of Female Genital Tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The 2020 WHO classification is focused on the distinction between
      HPV-associated and HPV-independent squamous cell carcinoma of the lower
      female genital organs.
    explanation: >-
      The WHO classification review supports HPV-associated versus
      HPV-independent classification for lower female genital squamous cell
      carcinoma, including vulvar squamous carcinoma.
prevalence:
- population: Global, 2022
  notes: >-
    The cited review also reports approximately 47,000 global cases in 2022.
    This record is a proportional disease-burden context, not a point-prevalence
    estimate or population incidence rate.
  evidence:
  - reference: PMID:38927973
    reference_title: "Imaging in Vulval Cancer."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Vulval cancer is a rare gynaecological cancer, accounting for 3% of all
      gynaecological malignancies, with 47,000 cases in 2022 globally.
    explanation: >-
      The review supplies a scope-safe global case count and proportion among
      gynecologic malignancies without implying a population prevalence rate.
has_subtypes:
- name: HPV-Associated VSCC
  display_name: HPV-associated vulvar squamous cell carcinoma
  description: >-
    Molecular subtype associated with high-risk human papillomavirus,
    p16 block staining and commonly non-keratinizing morphology, with generally
    better prognosis than HPV-independent disease.
  evidence:
  - reference: PMID:37840151
    reference_title: "TP53 mutation and human papilloma virus status as independent prognostic factors in a Norwegian cohort of vulva squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Vulva squamous cell carcinoma (VSCC) develops through two separate
      molecular pathways-one involving high-risk human papilloma virus
      infection (HPV-associated), and the other without HPV infection
      (HPV-independent) often involving TP53 mutation. HPV-associated VSCC
      generally has a better progression-free survival than HPV-independent
      VSCC.
    explanation: >-
      The cohort paper directly supports HPV-associated VSCC as a distinct
      molecular pathway and links it to better progression-free survival.
  - reference: DOI:10.1055/a-1545-4279
    reference_title: "2020 WHO Classification of Female Genital Tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HPV-associated VIN (usual VIN; u-VIN), b and c non-keratinizing,
      HPV-associated squamous cell carcinoma of the vulva with a plump pattern
      of invasion and p16 positivity (so-called block staining; see text)
    explanation: >-
      The WHO review directly links the HPV-associated precursor and carcinoma
      pathway to p16 block positivity and non-keratinizing VSCC morphology.
- name: HPV-Independent TP53-Altered VSCC
  display_name: HPV-independent TP53-altered vulvar squamous cell carcinoma
  description: >-
    Molecular subtype not driven by HPV, commonly keratinizing, enriched for
    TP53 alteration and other somatic lesions, and linked to differentiated VIN
    in a chronic inflammatory vulvar-skin context.
  evidence:
  - reference: PMID:37840151
    reference_title: "TP53 mutation and human papilloma virus status as independent prognostic factors in a Norwegian cohort of vulva squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Vulva squamous cell carcinoma (VSCC) develops through two separate
      molecular pathways-one involving high-risk human papilloma virus
      infection (HPV-associated), and the other without HPV infection
      (HPV-independent) often involving TP53 mutation.
    explanation: >-
      This abstract explicitly distinguishes the HPV-independent pathway and
      notes frequent TP53 mutation involvement.
  - reference: DOI:10.1055/a-1545-4279
    reference_title: "2020 WHO Classification of Female Genital Tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HPV-independent VIN (d-VIN), e and f keratinizing squamous cell carcinoma
      of the vulva with a netlike pattern of invasion and aberrant p53
      expression (see text).
    explanation: >-
      The WHO figure caption directly connects dVIN with keratinizing VSCC and
      aberrant p53 expression in the HPV-independent pathway.
  - reference: DOI:10.3390/cancers16244216
    reference_title: "Molecular Subtypes of Vulvar Squamous Cell Carcinoma: The Significance of HPV-Independent/p53 Wild Type"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      those that arise independently of HPV (HPVi), most commonly in the setting
      of a chronic inflammatory condition of the vulvar skin. This latter group
      of HPVi VSCC arises in most cases secondary to mutations in TP53
    explanation: >-
      The review directly links most HPV-independent VSCC to a chronic
      inflammatory vulvar-skin context and TP53 mutation.
- name: HPV-Independent p53-Wild-Type VSCC
  display_name: HPV-independent p53-wild-type vulvar squamous cell carcinoma
  description: >-
    Uncommon HPV-independent molecular subtype lacking abnormal p53
    immunophenotype, with intermediate prognosis between HPV-associated and
    HPV-independent TP53-altered disease.
  evidence:
  - reference: DOI:10.3390/cancers16244216
    reference_title: "Molecular Subtypes of Vulvar Squamous Cell Carcinoma: The Significance of HPV-Independent/p53 Wild Type"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This latter group of HPVi VSCC arises in most cases secondary to mutations
      in TP53, but recently, attention has focused on the uncommon TP53
      wild-type HPVi VSCC.
    explanation: >-
      The review explicitly identifies HPV-independent TP53-wild-type VSCC as an
      uncommon third molecular subgroup.
  - reference: DOI:10.3390/cancers16244216
    reference_title: "Molecular Subtypes of Vulvar Squamous Cell Carcinoma: The Significance of HPV-Independent/p53 Wild Type"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HPVa VSCC has the most favorable prognosis, while HPVi VSCC with TP53
      mutations (p53abn) has the worst prognosis, and HPVi VSCC with wild-type
      TP53 (p53wt) has an intermediate prognosis.
    explanation: >-
      This directly supports the intermediate prognosis assigned to the
      HPV-independent p53-wild-type subgroup.
infectious_agent:
- name: High-Risk Human Papillomavirus
  description: >-
    High-risk HPV infection drives the HPV-associated pathway of vulvar
    squamous cell carcinoma through viral oncogene effects and is commonly
    assessed by p16 immunohistochemistry or HPV RNA/DNA testing.
  infectious_agent_term:
    preferred_term: human papillomavirus
    term:
      id: NCBITaxon:10566
      label: Human papillomavirus
  evidence:
  - reference: PMID:37840151
    reference_title: "TP53 mutation and human papilloma virus status as independent prognostic factors in a Norwegian cohort of vulva squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Immunohistochemistry for p53, Ki67 and p16INK4A (a surrogate marker for
      HPV infection) was performed on formalin-fixed paraffin-embedded tissues
      from a cohort of surgically treated VSCC patients to identify molecular
      subtypes of VSCC. Presence of HPV infection was detected by HPV DNA PCR
      and HPV mRNA in situ hybridization (ISH).
    explanation: >-
      This cohort operationalizes HPV-associated VSCC using p16, HPV DNA PCR,
      and HPV mRNA ISH, supporting high-risk HPV as the infectious driver in
      this molecular subtype.
pathophysiology:
- name: High-Risk HPV Infection
  description: >-
    High-risk HPV infection defines one major etiologic pathway of
    vulvar squamous cell carcinoma and precedes viral-oncoprotein disruption of
    host tumor-suppressor control.
  evidence:
  - reference: PMID:37840151
    reference_title: "TP53 mutation and human papilloma virus status as independent prognostic factors in a Norwegian cohort of vulva squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Vulva squamous cell carcinoma (VSCC) develops through two separate
      molecular pathways-one involving high-risk human papilloma virus
      infection (HPV-associated), and the other without HPV infection
      (HPV-independent) often involving TP53 mutation.
    explanation: >-
      The human tumor cohort identifies high-risk HPV infection as one of the
      two principal molecular pathways of VSCC.
  cell_types:
  - preferred_term: vulvar keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  locations:
  - preferred_term: vulva
    term:
      id: UBERON:0000997
      label: mammalian vulva
  biological_processes:
  - preferred_term: response to virus
    term:
      id: GO:0009615
      label: response to virus
  downstream:
  - target: HPV E6-Mediated p53 Degradation
    description: Oncogenic HPV infection permits expression of E6, which targets p53.
  - target: HPV E7-Mediated pRB Binding
    description: Oncogenic HPV infection permits expression of E7, which binds pRB.
  - target: HPV-Associated High-Grade Squamous Intraepithelial Lesion (HSIL/uVIN)
    description: Persistent high-risk HPV infection defines the HPV-associated high-grade vulvar precursor pathway.
- name: HPV E6-Mediated p53 Degradation
  conforms_to: "viral_oncogenesis#Host Tumor Suppressor Inactivation and Signaling Hijack"
  biological_scale: MOLECULAR
  description: >-
    The high-risk HPV E6 oncoprotein binds p53 and stimulates its degradation
    through the ubiquitin-dependent protease system, weakening a central
    tumor-suppressor checkpoint in infected vulvar keratinocytes.
  evidence:
  - reference: PMID:2175676
    reference_title: "The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In this study we demonstrate that the E6 proteins of the oncogenic HPVs
      that bind p53 stimulate the degradation of p53.
    explanation: >-
      This classic mechanistic study directly supports E6-mediated p53
      degradation rather than inferring tumor-suppressor disruption from p16
      staining alone.
  - reference: PMID:25340830
    reference_title: "Viral carcinogenesis: factors inducing DNA damage and virus integration."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The HR HPV E6 protein induces ubiquitin-mediated degradation of p53,
      resulting in disabling of the normal cellular response to many insults,
      including the DNA damage response
    explanation: >-
      This viral-carcinogenesis review connects E6-mediated p53 degradation to
      loss of the host DNA-damage response modeled by this node.
  genes:
  - preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
  cell_types:
  - preferred_term: vulvar keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  biological_processes:
  - preferred_term: proteasome-mediated ubiquitin-dependent protein catabolic process
    modifier: INCREASED
    term:
      id: GO:0043161
      label: proteasome-mediated ubiquitin-dependent protein catabolic process
  downstream:
  - target: Clonal Squamous Cell Proliferation
    description: Loss of p53-mediated restraint permits survival and expansion of damaged keratinocytes.
- name: HPV E7-Mediated pRB Binding
  conforms_to: "viral_oncogenesis#Host Tumor Suppressor Inactivation and Signaling Hijack"
  biological_scale: MOLECULAR
  description: >-
    The high-risk HPV16 E7 oncoprotein binds the retinoblastoma protein pRB,
    disrupting RB-pathway control and enabling inappropriate cell-cycle entry
    in infected vulvar keratinocytes.
  evidence:
  - reference: PMID:2537532
    reference_title: "The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      These assays have been used to demonstrate that the E7 oncoprotein of the
      human papilloma virus type-16 can form similar complexes with p105-RB.
    explanation: >-
      The biochemical study directly demonstrates HPV16 E7 binding to the RB
      gene product and supports RB-pathway disruption in HPV-associated cancer.
  - reference: PMID:25340830
    reference_title: "Viral carcinogenesis: factors inducing DNA damage and virus integration."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      E7, another HPV oncogene, mimics this process by binding to pRB and
      releasing the E2F protein
    explanation: >-
      The review directly supports the modeled step from E7-pRB binding to E2F
      release.
  - reference: PMID:25340830
    reference_title: "Viral carcinogenesis: factors inducing DNA damage and virus integration."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      This results in the release of the E2F protein, which then activates the
      transcription of genes required for the S-phase transition
    explanation: >-
      The same review connects E2F release to transcriptional activation of the
      S-phase program, supporting increased G1/S transition in this node.
  genes:
  - preferred_term: RB1
    term:
      id: hgnc:9884
      label: RB1
  cell_types:
  - preferred_term: vulvar keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  biological_processes:
  - preferred_term: G1/S transition of mitotic cell cycle
    modifier: INCREASED
    term:
      id: GO:0000082
      label: G1/S transition of mitotic cell cycle
  downstream:
  - target: Clonal Squamous Cell Proliferation
    description: E7-associated loss of RB restraint promotes transformed keratinocyte proliferation.
- name: Lichen Sclerosus Inflammatory Microenvironment
  description: >-
    Lichen sclerosus creates chronic vulvar inflammation, tissue remodeling,
    oxidative stress, scarring, and symptoms that can precede or accompany
    HPV-independent vulvar squamous carcinogenesis.
  evidence:
  - reference: DOI:10.3389/fmed.2023.1106318
    reference_title: "Lichen sclerosus: The 2023 update"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Oxidative stress with lipid and DNA peroxidation provides an enabling
      microenvironment to autoimmunity and carcinogenesis.
    explanation: >-
      The review supports oxidative stress and immune-mediated tissue injury
      as a carcinogenesis-enabling microenvironment in lichen sclerosus.
  - reference: DOI:10.3389/fmed.2023.1106318
    reference_title: "Lichen sclerosus: The 2023 update"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In addition to genital scarring, and sexual and urinary dysfunction, LS
      may also lead to squamous cell carcinoma.
    explanation: >-
      This explicitly links lichen sclerosus to squamous cell carcinoma risk.
  cell_types:
  - preferred_term: vulvar keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  locations:
  - preferred_term: vulva
    term:
      id: UBERON:0000997
      label: mammalian vulva
  biological_processes:
  - preferred_term: extracellular matrix organization
    modifier: ABNORMAL
    term:
      id: GO:0030198
      label: extracellular matrix organization
  downstream:
  - target: HPV-Independent Somatic Driver Accumulation
    description: Chronic inflammatory and oxidative injury can create a permissive context for somatic driver selection.
  - target: Vulvar Pruritus
    description: Lichen sclerosus commonly produces vulvar itching.
  - target: Vulvar Pain or Soreness
    description: Lichen sclerosus commonly produces vulvar soreness and pain.
  - target: Differentiated Vulvar Intraepithelial Neoplasia (dVIN)
    description: Lichen sclerosus can provide a clinical context for the HPV-independent differentiated precursor pathway.
- name: HPV-Associated High-Grade Squamous Intraepithelial Lesion (HSIL/uVIN)
  biological_scale: TISSUE
  description: >-
    HPV-associated high-grade squamous intraepithelial lesion, historically
    usual-type VIN (uVIN or VIN 2/3), is the HPV-associated vulvar precursor.
    Compared with dVIN it generally has slower progression, and spontaneous
    regression can occur in the HPV-associated VIN spectrum.
  evidence:
  - reference: DOI:10.1055/a-1545-4279
    reference_title: "2020 WHO Classification of Female Genital Tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      With reference to vulvar intraepithelial neoplasias (VIN), the distinction
      between HPV-associated and HPV-negative neoplasia has been retained. In
      terms of nomenclature, HPV-associated VIN corresponds to low (VIN 1) and
      high-grade SIL (VIN 2 and 3;
    explanation: >-
      The WHO review maps HPV-associated VIN 2/3 to high-grade squamous
      intraepithelial lesion, supporting this precursor as distinct from dVIN.
  - reference: DOI:10.1055/a-1545-4279
    reference_title: "2020 WHO Classification of Female Genital Tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Spontaneous regression possible (especially VIN 1)
      Most common form of VIN
      Slower rate of progression squamous cell carcinomaVIN
    explanation: >-
      The WHO clinicopathologic figure supports slower progression and possible
      spontaneous regression in the HPV-associated VIN spectrum; the entry does
      not infer a numerical progression risk from this qualitative evidence.
  cell_types:
  - preferred_term: vulvar keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  locations:
  - preferred_term: vulva
    term:
      id: UBERON:0000997
      label: mammalian vulva
  biological_processes:
  - preferred_term: epithelial cell proliferation
    modifier: INCREASED
    term:
      id: GO:0050673
      label: epithelial cell proliferation
  downstream:
  - target: Clonal Squamous Cell Proliferation
    description: HPV-associated HSIL/uVIN can progress through further clonal expansion toward invasive carcinoma.
- name: Differentiated Vulvar Intraepithelial Neoplasia (dVIN)
  biological_scale: TISSUE
  description: >-
    Differentiated VIN is an HPV-independent precursor that occurs in older
    women and can arise in a lichen-sclerosus context. It has no expected spontaneous regression,
    progresses more rapidly than HPV-associated VIN, and is allocated to the
    more aggressive keratinizing squamous carcinoma pathway.
  evidence:
  - reference: DOI:10.1055/a-1545-4279
    reference_title: "2020 WHO Classification of Female Genital Tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The differentiated VIN with its horizontal spread (d-VIN) is a precursor
      lesion that is allocated to a more aggressive,
    explanation: >-
      The WHO review assigns dVIN to the more aggressive HPV-independent
      keratinizing squamous carcinoma precursor pathway.
  - reference: DOI:10.1055/a-1545-4279
    reference_title: "2020 WHO Classification of Female Genital Tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Less common form of VIN
      No spontaneous regression
      Older women
      Faster rate of progression VIN squamous cell carcinoma
    explanation: >-
      The WHO clinicopathologic figure supports the qualitative natural-history
      differences used here without assigning an unsupported numerical risk.
  - reference: DOI:10.3390/diagnostics14161799
    reference_title: "Squamous Cell Carcinoma In Situ—The Importance of Early Diagnosis in Bowen Disease, Vulvar Intraepithelial Neoplasia, Penile Intraepithelial Neoplasia, and Erythroplasia of Queyrat"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The histopathologic features, degree of differentiation, and associations
      with lichen planus, lichen sclerosus, and HPV guide the selection of
      conservative treatments or surgical excision.
    explanation: >-
      In this VIN-focused review, lichen sclerosus and HPV are explicit contexts
      used with differentiation to classify and manage vulvar precursor lesions.
  cell_types:
  - preferred_term: vulvar keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  locations:
  - preferred_term: vulva
    term:
      id: UBERON:0000997
      label: mammalian vulva
  biological_processes:
  - preferred_term: epithelial cell proliferation
    modifier: INCREASED
    term:
      id: GO:0050673
      label: epithelial cell proliferation
  downstream:
  - target: Clonal Squamous Cell Proliferation
    description: dVIN can progress through clonal expansion toward keratinizing invasive carcinoma.
- name: HPV-Independent Somatic Driver Accumulation
  description: >-
    HPV-independent VSCC is enriched for TERT promoter, TP53, CDKN2A, NOTCH1,
    and FAT1 alterations, supporting a tumor-suppressor and differentiation
    failure pathway distinct from HPV-driven tumors.
  evidence:
  - reference: PMID:34650187
    reference_title: "Molecular landscape of vulvovaginal squamous cell carcinoma: new insights into molecular mechanisms of HPV-associated and HPV-independent squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other common abnormalities in HPV-independent tumors were TP53 mutations
      (13/15, 87%), CDKN2A alterations (10/15, 67%), and NOTCH1 and FAT1
      mutations (7/15, 47% each).
    explanation: >-
      Sequencing of vulvovaginal squamous carcinomas identifies recurrent
      TP53, CDKN2A, NOTCH1, and FAT1 alterations in HPV-independent tumors.
  - reference: PMID:34650187
    reference_title: "Molecular landscape of vulvovaginal squamous cell carcinoma: new insights into molecular mechanisms of HPV-associated and HPV-independent squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cancer cell fraction analysis of HPV-independent squamous carcinomas
      suggests that TERT and/or NOTCH1 alterations along with TP53 alterations
      can be the initiating event in these tumors.
    explanation: >-
      The paper places TERT, NOTCH1, and TP53 alterations early in the
      HPV-independent carcinogenic pathway.
  genes:
  - preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
  - preferred_term: TERT
    term:
      id: hgnc:11730
      label: TERT
  - preferred_term: CDKN2A
    term:
      id: hgnc:1787
      label: CDKN2A
  - preferred_term: NOTCH1
    term:
      id: hgnc:7881
      label: NOTCH1
  - preferred_term: FAT1
    term:
      id: hgnc:3595
      label: FAT1
  cell_types:
  - preferred_term: vulvar keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  biological_processes:
  - preferred_term: apoptotic process
    modifier: DECREASED
    term:
      id: GO:0006915
      label: apoptotic process
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  downstream:
  - target: Differentiated Vulvar Intraepithelial Neoplasia (dVIN)
    description: Early HPV-independent somatic drivers can be selected within the differentiated precursor pathway.
  - target: Clonal Squamous Cell Proliferation
    description: Somatic driver alterations support malignant clonal expansion in vulvar keratinocytes.
- name: PIK3CA-Activated HPV-Associated Signaling
  conforms_to: "sustaining_proliferative_signaling#Constitutive Mitogenic Pathway Activation"
  description: >-
    HPV-associated vulvovaginal squamous carcinomas are enriched for PIK3CA
    activating mutations, implicating PI3K pathway activation in a subset of
    HPV-driven tumors.
  evidence:
  - reference: PMID:34650187
    reference_title: "Molecular landscape of vulvovaginal squamous cell carcinoma: new insights into molecular mechanisms of HPV-associated and HPV-independent squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HPV-associated vulvovaginal squamous cell carcinoma had PIK3CA
      activating mutations (7/11, 64%) as the most common genomic event
    explanation: >-
      This sequencing cohort supports PIK3CA activation as a recurrent event
      in HPV-associated vulvovaginal squamous carcinoma.
  genes:
  - preferred_term: PIK3CA
    term:
      id: hgnc:8975
      label: PIK3CA
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  downstream:
  - target: Clonal Squamous Cell Proliferation
    description: PI3K pathway activation supports tumor cell growth and survival.
- name: HRAS/RAS-MAPK Signaling Activation
  conforms_to: "sustaining_proliferative_signaling#Constitutive Mitogenic Pathway Activation"
  description: >-
    HRAS mutations occur in a subset of VSCC and implicate RAS/MAPK signaling as
    an additional proliferation pathway in vulvar squamous carcinoma.
  evidence:
  - reference: DOI:10.1038/s41598-024-63913-z
    reference_title: "Genomic profiles of Japanese patients with vulvar squamous cell carcinoma"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Somatic mutations were identified by targeted or panel sequencing, and TP53
      was identified as the most common mutation (52–81%), followed by HRAS
      (7–26%), CDKN2A (21–24%), and PIK3CA (5–10%).
    explanation: >-
      The Japanese VSCC sequencing cohort identifies recurrent HRAS mutations,
      supporting a RAS/MAPK-linked somatic driver mechanism.
  genes:
  - preferred_term: HRAS
    term:
      id: hgnc:5173
      label: HRAS
  biological_processes:
  - preferred_term: MAPK cascade
    modifier: INCREASED
    term:
      id: GO:0000165
      label: MAPK cascade
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  downstream:
  - target: Clonal Squamous Cell Proliferation
    description: HRAS-driven MAPK signaling can promote transformed keratinocyte proliferation.
- name: Clonal Squamous Cell Proliferation
  conforms_to: "sustaining_proliferative_signaling#Growth-Factor-Independent Proliferation"
  description: >-
    HPV-driven cell-cycle deregulation or HPV-independent somatic driver
    accumulation leads to clonal proliferation and invasive squamous carcinoma
    in the vulvar epithelium.
  cell_types:
  - preferred_term: vulvar keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  locations:
  - preferred_term: vulva
    term:
      id: UBERON:0000997
      label: mammalian vulva
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  downstream:
  - target: Squamous Cell Carcinoma
    description: Malignant clonal expansion produces invasive squamous carcinoma histology.
- name: Squamous Cell Carcinoma
  biological_scale: TISSUE
  description: >-
    Invasive squamous carcinoma is the dominant malignant histology of vulvar
    carcinoma and produces the local lesion phenotypes through tumor growth and
    tissue destruction.
  evidence:
  - reference: PMID:38791925
    reference_title: "Current Preoperative Management of Vulvar Squamous Cell Carcinoma: An Overview."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Vulvar squamous cell carcinoma (VSCC) is the most common type.
    explanation: >-
      The clinical review identifies VSCC as the predominant histologic type of
      vulvar carcinoma.
  cell_types:
  - preferred_term: vulvar squamous carcinoma cell
    term:
      id: CL:0000312
      label: keratinocyte
  locations:
  - preferred_term: vulva
    term:
      id: UBERON:0000997
      label: mammalian vulva
  downstream:
  - target: Biopsy-Requiring Vulvar Lesion
    description: Invasive growth produces a persistent or suspicious lesion requiring biopsy.
  - target: Vulvar Lump or Mass
    description: Expanding tumor can present clinically as a vulvar lump or mass.
  - target: Vulvar Ulcer
    description: Local tumor growth and tissue destruction can present as ulceration.
  - target: Vulvar Pruritus
    description: Vulvar squamous carcinoma commonly presents with vulvar pruritus.
  - target: Vulvar Pain or Soreness
    description: Vulvar squamous carcinoma commonly presents with vulvar pain.
  - target: Inguinofemoral Nodal Metastasis
    description: Invasive vulvar squamous carcinoma can spread to inguinofemoral lymph nodes.
  - target: Fibroblast-Supported Tumor Invasion
    description: Established tumor cells interact with cancer-associated fibroblasts during invasion.
- name: Inguinofemoral Nodal Metastasis
  biological_scale: TISSUE
  description: >-
    Regional spread to inguinofemoral lymph nodes is a major adverse prognostic
    event in vulvar cancer and defines the target of groin-directed treatment.
  evidence:
  - reference: DOI:10.3389/or.2024.1389035
    reference_title: "Adjuvant Radiotherapy for Groin Node Metastases Following Surgery for Vulvar Cancer: A Systematic Review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Nodal involvement and surgical margin status are the two most important
      prognostic factors for local and distant recurrence, representing the two
      main factors analyzed for recommending adjuvant therapy.
    explanation: >-
      The systematic review identifies nodal involvement as a principal
      prognostic factor and treatment-decision context.
  - reference: DOI:10.3389/or.2024.1389035
    reference_title: "Adjuvant Radiotherapy for Groin Node Metastases Following Surgery for Vulvar Cancer: A Systematic Review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      in women with resectable disease without nodal involvement, the 5-year OS
      rate is more than 80%, while it falls dramatically to less than 40% in
      women with inguinal nodal involvement
    explanation: >-
      This directly supports the adverse prognostic significance of inguinal
      nodal involvement without extrapolating to an individual prognosis.
  locations:
  - preferred_term: inguinal lymph node
    term:
      id: UBERON:0001542
      label: inguinal lymph node
- name: Fibroblast-Supported Tumor Invasion
  biological_scale: TISSUE
  description: >-
    Cancer-associated fibroblasts support invasion and tumor formation by a
    lichen-sclerosus-associated VSCC cell line in organotypic culture and
    xenograft models, implicating stromal support in local progression.
  evidence:
  - reference: PMID:31654625
    reference_title: "Establishment of a novel cancer cell line derived from vulvar carcinoma associated with lichen sclerosus exhibiting a fibroblast-dependent tumorigenic potential."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In vitro 3D organotypic assays and in vivo xenografts revealed a prominent
      role of cancer-associated fibroblasts in VCC1 invasion and tumor formation.
    explanation: >-
      The in vitro component of the reported combined result supports
      fibroblast-dependent invasion in 3D organotypic assays.
  - reference: PMID:31654625
    reference_title: "Establishment of a novel cancer cell line derived from vulvar carcinoma associated with lichen sclerosus exhibiting a fibroblast-dependent tumorigenic potential."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In vitro 3D organotypic assays and in vivo xenografts revealed a prominent
      role of cancer-associated fibroblasts in VCC1 invasion and tumor formation.
    explanation: >-
      The in vivo xenograft component independently supports fibroblast-dependent
      tumor formation in a model-organism context.
  cell_types:
  - preferred_term: cancer-associated fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  - preferred_term: vulvar squamous carcinoma cell
    term:
      id: CL:0000312
      label: keratinocyte
  biological_processes:
  - preferred_term: cell migration
    modifier: INCREASED
    term:
      id: GO:0016477
      label: cell migration
histopathology:
- name: HPV-Associated High-Grade Squamous Intraepithelial Lesion (HSIL/uVIN)
  finding_term:
    preferred_term: high-grade vulvar squamous intraepithelial lesion
    term:
      id: NCIT:C4761
      label: High Grade Vulvar Squamous Intraepithelial Lesion
  diagnostic: true
  description: >-
    HPV-associated vulvar HSIL corresponds to usual-type VIN 2/3. Histopathology
    is the diagnostic standard, and p16 expression is used as a surrogate of
    HPV association.
  evidence:
  - reference: DOI:10.1055/a-1545-4279
    reference_title: "2020 WHO Classification of Female Genital Tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Immunohistochemical p16 expression is considered to be a surrogate marker
      for HPV association.
    explanation: >-
      The WHO review supports p16 expression as a surrogate marker of the
      HPV-associated precursor pathway.
  - reference: PMID:39202286
    reference_title: "Squamous Cell Carcinoma In Situ-The Importance of Early Diagnosis in Bowen Disease, Vulvar Intraepithelial Neoplasia, Penile Intraepithelial Neoplasia, and Erythroplasia of Queyrat."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Histopathological examination represents the gold-standard diagnosis in
      VIN and PeIN, while p16 and p53 immunostainings alongside HPV testing
      provide crucial diagnostic clues.
    explanation: >-
      This supports histopathology as the VIN diagnostic standard and molecular
      testing as classification evidence rather than as a substitute for biopsy.
- name: Differentiated Vulvar Intraepithelial Neoplasia (dVIN)
  finding_term:
    preferred_term: HPV-independent vulvar intraepithelial neoplasia
    term:
      id: NCIT:C37272
      label: Vulvar Intraepithelial Neoplasia, HPV-Independent
  diagnostic: true
  description: >-
    dVIN is an HPV-independent precursor commonly associated with lichen
    sclerosus, aberrant p53 expression, and the keratinizing VSCC pathway.
  evidence:
  - reference: DOI:10.1055/a-1545-4279
    reference_title: "2020 WHO Classification of Female Genital Tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HPV-independent VIN (d-VIN), e and f keratinizing squamous cell carcinoma
      of the vulva with a netlike pattern of invasion and aberrant p53
      expression (see text).
    explanation: >-
      The WHO figure caption directly supports the dVIN, aberrant-p53, and
      keratinizing carcinoma association.
  - reference: PMID:39202286
    reference_title: "Squamous Cell Carcinoma In Situ-The Importance of Early Diagnosis in Bowen Disease, Vulvar Intraepithelial Neoplasia, Penile Intraepithelial Neoplasia, and Erythroplasia of Queyrat."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Histopathological examination represents the gold-standard diagnosis in
      VIN and PeIN, while p16 and p53 immunostainings alongside HPV testing
      provide crucial diagnostic clues.
    explanation: >-
      This supports histopathology plus p53/p16/HPV evidence for distinguishing
      differentiated HPV-independent VIN from HPV-associated HSIL.
- name: Squamous Cell Carcinoma
  finding_term:
    preferred_term: Squamous Cell Carcinoma
    term:
      id: NCIT:C2929
      label: Squamous Cell Carcinoma
  diagnostic: true
  description: >-
    Vulvar squamous cell carcinoma is the most common histologic type of
    vulvar carcinoma.
  evidence:
  - reference: PMID:38791925
    reference_title: "Current Preoperative Management of Vulvar Squamous Cell Carcinoma: An Overview."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Vulvar squamous cell carcinoma (VSCC) is the most common type.
    explanation: >-
      This review supports squamous cell carcinoma as the dominant vulvar
      carcinoma histology.
phenotypes:
- category: Gynecologic
  name: Biopsy-Requiring Vulvar Lesion
  diagnostic: true
  description: >-
    A persistent or suspicious vulvar lesion requires biopsy to establish or
    exclude vulvar carcinoma.
  phenotype_term:
    preferred_term: vulvar lesion
    term:
      id: HP:0011355
      label: Localized skin lesion
  evidence:
  - reference: PMID:38791925
    reference_title: "Current Preoperative Management of Vulvar Squamous Cell Carcinoma: An Overview."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diagnosis relies on biopsy during vulvoscopy, plus imaging such as
      ultrasonography (USG), magnetic resonance imaging (MRI) and positron
      emission tomography (PET).
    explanation: >-
      The need for vulvoscopy-directed biopsy supports a visible or clinically
      suspicious vulvar lesion as the diagnostic presentation.
- category: Gynecologic
  name: Vulvar Lump or Mass
  description: >-
    Patients with vulvar cancer may notice a vulvar lump or mass as part of the
    presenting lesion complex.
  phenotype_term:
    preferred_term: vulvar neoplasm
    term:
      id: HP:0030416
      label: Vulvar neoplasm
  evidence:
  - reference: DOI:10.1002/ijgo.13881
    reference_title: "Cancer of the vulva: 2021 update"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While vulvar cancer may be asymptomatic, most women present with vulvar
      pruritus or pain, or have noticed a lump or ulcer.
    explanation: >-
      The clinical update identifies a noticed lump as a presenting feature of
      vulvar cancer, represented by the vulvar-specific HPO neoplasm term.
- category: Dermatologic
  name: Vulvar Ulcer
  description: >-
    Ulceration can be part of the presenting vulvar lesion complex in vulvar
    cancer.
  phenotype_term:
    preferred_term: vulvar ulcer
    term:
      id: HP:0200042
      label: Skin ulcer
  evidence:
  - reference: DOI:10.1002/ijgo.13881
    reference_title: "Cancer of the vulva: 2021 update"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While vulvar cancer may be asymptomatic, most women present with vulvar
      pruritus or pain, or have noticed a lump or ulcer.
    explanation: >-
      The clinical update identifies ulcer as a presenting feature; the HPO
      binding uses the broader skin-ulcer term because local HPO did not provide
      a vulvar-specific ulcer term.
- category: Dermatologic
  name: Vulvar Pruritus
  description: >-
    Vulvar pruritus is a common presenting symptom of vulvar cancer and can also
    occur in lichen sclerosus associated with the HPV-independent pathway.
  phenotype_term:
    preferred_term: pruritus vulvae
    term:
      id: HP:0032004
      label: Pruritus vulvae
  evidence:
  - reference: DOI:10.1002/ijgo.13881
    reference_title: "Cancer of the vulva: 2021 update"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While vulvar cancer may be asymptomatic, most women present with vulvar
      pruritus or pain, or have noticed a lump or ulcer.
    explanation: >-
      The disease-specific clinical review directly supports vulvar pruritus as
      a presenting symptom of vulvar cancer.
  - reference: DOI:10.3389/fmed.2023.1106318
    reference_title: "Lichen sclerosus: The 2023 update"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The typical clinical picture includes chronic whitish atrophic patches
      along with itching and soreness in the vulvar, perianal and penile
      regions.
    explanation: >-
      This supports pruritus in lichen sclerosus, an important associated
      precursor/risk setting for HPV-independent vulvar carcinoma.
- category: Dermatologic
  name: Vulvar Pain or Soreness
  description: >-
    Vulvar pain is a common presenting symptom of vulvar cancer and may also
    occur in associated vulvar dermatoses.
  phenotype_term:
    preferred_term: vulvodynia
    term:
      id: HP:0030943
      label: Vulvodynia
  evidence:
  - reference: DOI:10.1002/ijgo.13881
    reference_title: "Cancer of the vulva: 2021 update"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While vulvar cancer may be asymptomatic, most women present with vulvar
      pruritus or pain, or have noticed a lump or ulcer.
    explanation: >-
      The disease-specific clinical review directly supports vulvar pain as a
      presenting symptom of vulvar cancer.
  - reference: DOI:10.3389/fmed.2023.1106318
    reference_title: "Lichen sclerosus: The 2023 update"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The typical clinical picture includes chronic whitish atrophic patches
      along with itching and soreness in the vulvar, perianal and penile
      regions.
    explanation: >-
      This supports vulvar soreness in lichen sclerosus, a clinically relevant
      associated dermatosis in the HPV-independent disease pathway.
progression:
- phase: HPV-associated HSIL/uVIN precursor lesion to invasive carcinoma
  notes: >-
    HPV-associated VIN 2/3 corresponds to HSIL. Its progression toward squamous
    carcinoma is generally slower than dVIN, and spontaneous regression can
    occur within the HPV-associated VIN spectrum, especially in lower-grade VIN.
  evidence:
  - reference: DOI:10.1055/a-1545-4279
    reference_title: "2020 WHO Classification of Female Genital Tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Spontaneous regression possible (especially VIN 1)
      Most common form of VIN
      Slower rate of progression squamous cell carcinomaVIN
    explanation: >-
      The WHO review supplies a qualitative, subtype-specific natural-history
      comparison; no unsupported numerical transition probability is inferred.
- phase: Differentiated VIN precursor lesion to invasive carcinoma
  notes: >-
    dVIN is less common, occurs in older women, can accompany lichen
    sclerosus, has no expected spontaneous regression, and progresses more
    rapidly toward squamous carcinoma than HPV-associated VIN.
  evidence:
  - reference: DOI:10.1055/a-1545-4279
    reference_title: "2020 WHO Classification of Female Genital Tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Less common form of VIN
      No spontaneous regression
      Older women
      Faster rate of progression VIN squamous cell carcinoma
    explanation: >-
      This directly supports the calibrated qualitative natural history of dVIN.
  - reference: DOI:10.3390/diagnostics14161799
    reference_title: "Squamous Cell Carcinoma In Situ—The Importance of Early Diagnosis in Bowen Disease, Vulvar Intraepithelial Neoplasia, Penile Intraepithelial Neoplasia, and Erythroplasia of Queyrat"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The histopathologic features, degree of differentiation, and associations
      with lichen planus, lichen sclerosus, and HPV guide the selection of
      conservative treatments or surgical excision.
    explanation: >-
      The VIN-focused review supports lichen sclerosus as a precursor-lesion
      context; the progression-rate comparison remains sourced to WHO.
- phase: Vulvar lichen sclerosus-associated risk surveillance
  notes: >-
    Vulvar lichen sclerosus carries a long-term vulvar-cancer risk that rises
    over extended follow-up, supporting early detection of premalignant lesions
    and lifelong surveillance rather than a fixed short surveillance window.
  evidence:
  - reference: DOI:10.3389/fmed.2023.1106318
    reference_title: "Lichen sclerosus: The 2023 update"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the cumulative probability of progression to vulvar cancer escalates from
      1.2% at 2 years to 36.8% at 25 years
    explanation: >-
      The review reports increasing long-term cumulative progression in a VLS
      cohort and supports sustained surveillance in this specific risk context.
stages:
- name: FIGO 2021 Vulvar Carcinoma Staging
  description: >-
    The data-derived 2021 FIGO system stages vulvar carcinoma across Stages I
    through IV, incorporates tumor, nodal, and distant-disease characteristics,
    and permits cross-sectional imaging findings to contribute to staging.
  evidence:
  - reference: PMID:34520062
    reference_title: "FIGO staging for carcinoma of the vulva: 2021 revision."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The resulting new staging for carcinoma of the vulva has two substages in
      Stage I, no substage in Stage II, three substages in Stage III, and two
      substages in Stage IV.
    explanation: >-
      The FIGO revision defines the current stage and substage structure from a
      12,063-case dataset.
  - reference: PMID:34520062
    reference_title: "FIGO staging for carcinoma of the vulva: 2021 revision."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This revision has a new definition for depth of invasion, uses the same
      definition for lymph node metastases utilized in cervical cancer, and
      allows findings from cross-sectional imaging to be incorporated into
      vulvar cancer staging.
    explanation: >-
      This directly supports the invasion-depth, nodal, and imaging components
      of the 2021 FIGO staging framework.
genetic:
- name: TP53
  association: Somatic Mutation
  gene_term:
    preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
  notes: >-
    TP53 mutations are frequent in HPV-independent VSCC and correlate with
    poorer progression-free survival.
  evidence:
  - reference: PMID:37840151
    reference_title: "TP53 mutation and human papilloma virus status as independent prognostic factors in a Norwegian cohort of vulva squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The TP53 mutation status was identified as an independent prognostic
      factor of worse progression-free survival (p = 0.024) after adjustment
      for FIGO stage.
    explanation: >-
      This cohort supports TP53 mutation as a prognostic somatic alteration in
      VSCC.
- name: PIK3CA
  association: Somatic Activating Mutation
  gene_term:
    preferred_term: PIK3CA
    term:
      id: hgnc:8975
      label: PIK3CA
  notes: >-
    PIK3CA activating mutations are enriched in HPV-associated vulvovaginal
    squamous carcinomas.
  evidence:
  - reference: PMID:34650187
    reference_title: "Molecular landscape of vulvovaginal squamous cell carcinoma: new insights into molecular mechanisms of HPV-associated and HPV-independent squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HPV-associated vulvovaginal squamous cell carcinoma had PIK3CA
      activating mutations (7/11, 64%) as the most common genomic event
    explanation: >-
      This supports PIK3CA activation as a recurrent molecular event in the
      HPV-associated pathway.
- name: TERT
  association: Somatic Promoter Alteration
  gene_term:
    preferred_term: TERT
    term:
      id: hgnc:11730
      label: TERT
  notes: >-
    TERT promoter alterations are highly enriched in HPV-independent
    vulvovaginal squamous carcinomas.
  evidence:
  - reference: PMID:34650187
    reference_title: "Molecular landscape of vulvovaginal squamous cell carcinoma: new insights into molecular mechanisms of HPV-associated and HPV-independent squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TERT gene alterations, mainly TERT promoter mutations (14/15 cases, 93%)
      featured significantly in HPV-independent carcinomas.
    explanation: >-
      This supports TERT promoter alteration as a frequent HPV-independent
      VSCC driver event.
- name: CDKN2A
  association: Somatic Alteration
  gene_term:
    preferred_term: CDKN2A
    term:
      id: hgnc:1787
      label: CDKN2A
  notes: >-
    CDKN2A alterations occur in HPV-independent tumors and remove an important
    cell-cycle restraint.
  evidence:
  - reference: PMID:34650187
    reference_title: "Molecular landscape of vulvovaginal squamous cell carcinoma: new insights into molecular mechanisms of HPV-associated and HPV-independent squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other common abnormalities in HPV-independent tumors were TP53 mutations
      (13/15, 87%), CDKN2A alterations (10/15, 67%), and NOTCH1 and FAT1
      mutations (7/15, 47% each).
    explanation: >-
      This supports CDKN2A alteration as a recurrent somatic event in the
      HPV-independent molecular subgroup.
- name: NOTCH1
  association: Somatic Mutation
  gene_term:
    preferred_term: NOTCH1
    term:
      id: hgnc:7881
      label: NOTCH1
  notes: >-
    NOTCH1 mutations are recurrent in HPV-independent vulvovaginal squamous
    carcinomas and may occur early with TP53 alterations.
  evidence:
  - reference: PMID:34650187
    reference_title: "Molecular landscape of vulvovaginal squamous cell carcinoma: new insights into molecular mechanisms of HPV-associated and HPV-independent squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other common abnormalities in HPV-independent tumors were TP53 mutations
      (13/15, 87%), CDKN2A alterations (10/15, 67%), and NOTCH1 and FAT1
      mutations (7/15, 47% each).
    explanation: >-
      This supports NOTCH1 mutation as a recurrent somatic event in
      HPV-independent vulvovaginal squamous carcinoma.
- name: FAT1
  association: Somatic Mutation
  gene_term:
    preferred_term: FAT1
    term:
      id: hgnc:3595
      label: FAT1
  notes: >-
    FAT1 mutations recur in HPV-independent vulvovaginal squamous carcinomas.
  evidence:
  - reference: PMID:34650187
    reference_title: "Molecular landscape of vulvovaginal squamous cell carcinoma: new insights into molecular mechanisms of HPV-associated and HPV-independent squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other common abnormalities in HPV-independent tumors were TP53 mutations
      (13/15, 87%), CDKN2A alterations (10/15, 67%), and NOTCH1 and FAT1
      mutations (7/15, 47% each).
    explanation: >-
      This supports FAT1 mutation as a recurrent somatic event in
      HPV-independent vulvovaginal squamous carcinoma.
- name: HRAS
  association: Somatic Mutation
  gene_term:
    preferred_term: HRAS
    term:
      id: hgnc:5173
      label: HRAS
  notes: >-
    HRAS mutations occur in a subset of VSCC and support RAS/MAPK pathway
    involvement.
  evidence:
  - reference: DOI:10.1038/s41598-024-63913-z
    reference_title: "Genomic profiles of Japanese patients with vulvar squamous cell carcinoma"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Somatic mutations were identified by targeted or panel sequencing, and TP53
      was identified as the most common mutation (52–81%), followed by HRAS
      (7–26%), CDKN2A (21–24%), and PIK3CA (5–10%).
    explanation: >-
      This supports HRAS as a recurrent somatic mutation in Japanese VSCC
      sequencing cohorts.
biochemical:
- name: p16 Immunohistochemistry
  notes: >-
    p16INK4A immunohistochemistry is used as a surrogate marker for HPV
    infection in VSCC molecular subtyping.
  readouts:
  - target: High-Risk HPV Infection
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Block-type p16 staining is a reliable but imperfect surrogate readout of
      HPV association and does not itself identify an HPV genotype.
    evidence:
    - reference: DOI:10.1055/a-1545-4279
      reference_title: "2020 WHO Classification of Female Genital Tumors"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Immunohistochemical p16 expression is considered to be a surrogate
        marker for HPV association.
      explanation: >-
        The WHO review directly supports p16 expression as a surrogate readout
        of HPV association.
  evidence:
  - reference: PMID:37840151
    reference_title: "TP53 mutation and human papilloma virus status as independent prognostic factors in a Norwegian cohort of vulva squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Immunohistochemistry for p53, Ki67 and p16INK4A (a surrogate marker for
      HPV infection) was performed on formalin-fixed paraffin-embedded tissues
      from a cohort of surgically treated VSCC patients to identify molecular
      subtypes of VSCC.
    explanation: >-
      The study supports p16INK4A immunohistochemistry as an HPV-associated
      subtype marker in VSCC.
- name: p53 Immunohistochemistry
  notes: >-
    Aberrant p53 immunohistochemical patterns correlate with underlying TP53
    mutation and help stratify HPV-independent VSCC; sequencing is required
    when mutation status itself must be established.
  readouts:
  - target: HPV-Independent Somatic Driver Accumulation
    relationship: CORRELATES_WITH
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      An aberrant p53 staining pattern supports the TP53-altered
      HPV-independent pathway but is not represented as a direct sequencing
      measurement of every somatic driver in this node.
    evidence:
    - reference: DOI:10.1055/a-1545-4279
      reference_title: "2020 WHO Classification of Female Genital Tumors"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Analysis using p53 immunohistochemistry may help to more accurately
        diagnose VIN and vulvar squamous cell carcinoma
      explanation: >-
        The WHO review supports p53 immunohistochemistry as a diagnostic
        correlate rather than a direct mutation assay.
  evidence:
  - reference: PMID:37840151
    reference_title: "TP53 mutation and human papilloma virus status as independent prognostic factors in a Norwegian cohort of vulva squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The results of p53 and p16INK4A immunohistochemistry confirmed three
      VSCC subtypes associated with different prognosis.
    explanation: >-
      This supports combined p53 and p16 immunohistochemistry for molecular
      stratification of VSCC.
environmental:
- name: Cigarette Smoking Exposure
  description: >-
    Cigarette smoking is an epidemiologic risk factor for vulvar cancer. The
    evidence supports a predisposing association, while the intermediate
    vulvar-carcinogenesis mechanism remains unspecified.
  exposure_term:
    preferred_term: cigarette smoking exposure
    term:
      id: ECTO:0100003
      label: exposure to cigarette smoking
  influences_mechanisms:
  - target: Squamous Cell Carcinoma
    environmental_effect: PREDISPOSES
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Smoking increases vulvar-cancer risk through incompletely resolved
      intermediates and is therefore modeled as predisposing rather than as a
      direct tumor-triggering event.
    evidence:
    - reference: PMID:38503056
      reference_title: "Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Known risk factors for vulvar cancer include increasing age, infection
        with human papillomavirus, cigarette smoking, inflammatory conditions
        affecting the vulva, and immunodeficiency.
      explanation: >-
        The guideline lists cigarette smoking as a vulvar-cancer risk factor but
        does not establish a direct molecular route, supporting this calibrated edge.
  evidence:
  - reference: PMID:38503056
    reference_title: "Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Known risk factors for vulvar cancer include increasing age, infection
      with human papillomavirus, cigarette smoking, inflammatory conditions
      affecting the vulva, and immunodeficiency.
    explanation: >-
      The NCCN guideline summary directly supports cigarette smoking as an
      epidemiologic risk factor for vulvar cancer.
diagnosis:
- name: Biopsy of a Suspicious Vulvar Lesion
  description: >-
    A persistent or suspicious vulvar lesion requires biopsy to exclude
    invasion and establish histologic diagnosis.
  diagnosis_term:
    preferred_term: biopsy procedure
    term:
      id: NCIT:C15189
      label: Biopsy Procedure
  results: Histopathologic confirmation or exclusion of invasive vulvar carcinoma.
  evidence:
  - reference: PMID:34669204
    reference_title: "Cancer of the vulva: 2021 update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Therefore, any suspicious vulvar lesion should be biopsied to exclude
      invasion.
    explanation: >-
      The clinical update directly supports biopsy of suspicious vulvar
      lesions to determine whether invasion is present.
- name: Preoperative Imaging for Local, Nodal, and Distant Disease
  description: >-
    Imaging complements clinical assessment for staging, with modality choice
    tailored to local extension, groin nodes, and suspected distant metastasis.
  diagnosis_term:
    preferred_term: imaging procedure
    term:
      id: NCIT:C17369
      label: Imaging Procedure
  results: Extent of primary, nodal, and distant vulvar cancer involvement.
  evidence:
  - reference: PMID:38927973
    reference_title: "Imaging in Vulval Cancer."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Various imaging modalities are widely used in conjunction with clinical
      assessment in the diagnosis and staging of vulval cancers; however, there
      is significant heterogeneity in which modalities are recommended in
      international guidelines, reflecting the paucity of evidence in this
      area.
    explanation: >-
      The imaging review supports imaging as an adjunct to clinical diagnosis
      and staging while preserving uncertainty about the optimal modality.
  - reference: PMID:38927973
    reference_title: "Imaging in Vulval Cancer."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For distant metastases, CT CAP and FDG-PET/CT have the most evidence to
      support their use.
    explanation: >-
      This supports CT chest/abdomen/pelvis and FDG-PET/CT when distant
      metastatic assessment is required.
- name: p16 and p53 Immunohistochemical Subtyping With Selective HPV Testing
  description: >-
    Histopathology with p16 and p53 immunostaining supports assignment of
    HPV-associated, HPV-independent p53-abnormal, and HPV-independent
    p53-wild-type VSCC. HPV DNA PCR or HPV mRNA in situ hybridization can
    document or resolve HPV status in selected cases; this entry does not claim
    that direct HPV testing is universally required for every tumor.
  diagnosis_term:
    preferred_term: immunohistochemistry
    term:
      id: NCIT:C23020
      label: Immunohistochemistry Staining Method
  results: Assignment of a prognostically meaningful VSCC molecular subtype.
  evidence:
  - reference: DOI:10.3390/cancers16244216
    reference_title: "Molecular Subtypes of Vulvar Squamous Cell Carcinoma: The Significance of HPV-Independent/p53 Wild Type"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The molecular subtyping of VSCC shows high reproducibility and provides
      important prognostic information.
    explanation: >-
      The review supports molecular subtyping as reproducible and prognostically
      informative without relying on its grammatically ambiguous diagnostic sentence.
  - reference: PMID:37840151
    reference_title: "TP53 mutation and human papilloma virus status as independent prognostic factors in a Norwegian cohort of vulva squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Immunohistochemistry for p53, Ki67 and p16INK4A (a surrogate marker for
      HPV infection) was performed on formalin-fixed paraffin-embedded tissues
      from a cohort of surgically treated VSCC patients to identify molecular
      subtypes of VSCC. Presence of HPV infection was detected by HPV DNA PCR
      and HPV mRNA in situ hybridization (ISH).
    explanation: >-
      This cohort demonstrates a practical workflow using p16/p53
      immunohistochemistry plus direct HPV DNA/RNA assays to establish subtype.
  - reference: DOI:10.3390/diagnostics14161799
    reference_title: "Squamous Cell Carcinoma In Situ—The Importance of Early Diagnosis in Bowen Disease, Vulvar Intraepithelial Neoplasia, Penile Intraepithelial Neoplasia, and Erythroplasia of Queyrat"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Histopathological examination represents the gold-standard diagnosis in
      VIN and PeIN, while p16 and p53 immunostainings alongside HPV testing
      provide crucial diagnostic clues.
    explanation: >-
      The review frames p16, p53, and HPV testing as diagnostic clues alongside
      histopathology, supporting calibrated rather than universally mandatory wording.
treatments:
- name: Local Excision With Sentinel Node Biopsy
  description: >-
    Early-stage vulvar cancer is treated by local excision of the primary
    tumor with sentinel node biopsy when nodal assessment is indicated, reducing
    morbidity compared with inguinofemoral lymphadenectomy in appropriate
    patients.
  evidence:
  - reference: DOI:10.6004/jnccn.2024.7002
    reference_title: "Update on the Sentinel Node Procedure in Vulvar Cancer"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early-stage vulvar cancer is managed by a local excision of the primary
      tumor and, if indicated, a sentinel node (SN) biopsy to assess the need
      for further groin treatment.
    explanation: >-
      This review supports local excision and sentinel node biopsy as standard
      early-stage management.
  therapeutic_modality: SURGERY
  target_mechanisms:
  - target: Squamous Cell Carcinoma
    treatment_effect: INHIBITS
    description: Local excision removes the invasive primary tumor.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
- name: Inguinofemoral Radiotherapy for Sentinel-Node Micrometastases
  description: >-
    In patients with sentinel-node micrometastases, inguinofemoral radiotherapy
    is a groin-treatment alternative to inguinofemoral lymphadenectomy with
    comparable efficacy and lower treatment-related morbidity. This evidence
    does not support a blanket definitive or adjuvant radiotherapy claim.
  evidence:
  - reference: DOI:10.6004/jnccn.2024.7002
    reference_title: "Update on the Sentinel Node Procedure in Vulvar Cancer"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Inguinofemoral radiotherapy is a good alternative to IFL in patients
      with micrometastases in the SN, with comparable efficacy and less
      treatment-related morbidity.
    explanation: >-
      The sentinel-node review supports only the selected micrometastatic
      sentinel-node context curated here.
  therapeutic_modality: RADIOTHERAPY
  target_mechanisms:
  - target: Inguinofemoral Nodal Metastasis
    treatment_effect: INHIBITS
    description: Groin-directed radiotherapy controls micrometastatic inguinofemoral nodal disease.
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: NCIT:C15313
      label: Radiation Therapy
- name: Adjuvant Radiotherapy for Resected Node-Positive Disease
  description: >-
    After surgery for inguinofemoral node-positive vulvar cancer, adjuvant
    radiotherapy may reduce groin recurrence. The systematic-review evidence is
    explicitly very low certainty, so this entry does not claim a definitive
    overall-survival benefit or universal indication.
  evidence:
  - reference: DOI:10.3389/or.2024.1389035
    reference_title: "Adjuvant Radiotherapy for Groin Node Metastases Following Surgery for Vulvar Cancer: A Systematic Review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Three (5.3%) versus 13 (24.1%) groin recurrences were noted, respectively,
      in the adjuvant radiotherapy and pelvic lymphadenectomy groups.
    explanation: >-
      The single eligible randomized trial reported fewer groin recurrences
      after adjuvant radiotherapy than after pelvic lymphadenectomy.
  - reference: DOI:10.3389/or.2024.1389035
    reference_title: "Adjuvant Radiotherapy for Groin Node Metastases Following Surgery for Vulvar Cancer: A Systematic Review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There is only very low-quality evidence on administering adjuvant
      radiotherapy for inguinal lymph node metastases.
    explanation: >-
      The review's certainty statement limits this treatment claim and prevents
      extrapolation to broad definitive or routine adjuvant radiotherapy.
  therapeutic_modality: RADIOTHERAPY
  target_mechanisms:
  - target: Inguinofemoral Nodal Metastasis
    treatment_effect: INHIBITS
    description: Adjuvant groin radiotherapy aims to control residual regional nodal disease after surgery.
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: NCIT:C15313
      label: Radiation Therapy
- name: Concurrent Chemoradiotherapy for Advanced Tumors
  description: >-
    Concurrent chemoradiotherapy is an effective alternative to surgery for
    advanced vulvar tumors, particularly when curative resection would be
    infeasible or excessively morbid.
  evidence:
  - reference: PMID:34669204
    reference_title: "Cancer of the vulva: 2021 update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treatment is predominantly surgical, particularly for squamous cell
      carcinoma, although concurrent chemoradiation is an effective alternative,
      particularly for advanced tumors.
    explanation: >-
      The clinical update directly supports concurrent chemoradiation as an
      alternative for advanced vulvar tumors.
  therapeutic_modality: RADIOTHERAPY
  target_mechanisms:
  - target: Squamous Cell Carcinoma
    treatment_effect: INHIBITS
    description: Concurrent chemoradiotherapy provides local tumor control in selected advanced VSCC.
  treatment_term:
    preferred_term: chemoradiotherapy
    term:
      id: NCIT:C94626
      label: Chemoradiotherapy
- name: First-Line Platinum-Based Chemotherapy Context in Advanced or Recurrent VSCC
  description: >-
    An ongoing maintenance trial enrolls patients after four to six cycles of
    first-line platinum-based chemotherapy for advanced or recurrent VSCC not
    amenable to curative surgery. This establishes a trial-treatment context,
    not comparative efficacy or a universal standard-of-care recommendation.
  evidence:
  - reference: clinicaltrials:NCT07101848
    reference_title: "A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This is a phase II, randomized study that will include 42 participants who
      have received 4 to 6 cycles of first-line platinum-based chemotherapy for
      advanced vulvar squamous cell carcinoma (SCC) not amenable to curative
      surgical treatment (FIGO 2018 stages III-IV - International Federation of
      Gynecology and Obstetrics) /
    explanation: >-
      The trial summary explicitly requires prior first-line platinum-based
      chemotherapy and therefore supports only the calibrated context stated here.
  target_mechanisms:
  - target: Squamous Cell Carcinoma
    treatment_effect: INHIBITS
    description: Platinum-based cytotoxic chemotherapy is directed at advanced or recurrent VSCC tumor burden in this trial context.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
    therapeutic_agent:
    - preferred_term: platinum compound
      term:
        id: NCIT:C1450
        label: Platinum Compound
- name: HPV Vaccination
  description: >-
    Prophylactic HPV vaccination is a prevention strategy intended to reduce the
    future burden of HPV-related cancers, including HPV-associated vulvar cancer.
  evidence:
  - reference: DOI:10.3390/vaccines12111291
    reference_title: "Human Papillomavirus-Related Cancer Vaccine Strategies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Vaccination against HPV can effectively block the transmission of the
      virus and prevent HPV-related cancers.
    explanation: >-
      The vaccine review directly supports prophylactic HPV vaccination as
      prevention of HPV infection transmission and HPV-related cancers,
      explicitly including vulvar cancer in its scope.
  - reference: DOI:10.1001/jamanetworkopen.2024.31807
    reference_title: "Human Papillomavirus Vaccination and Human Papillomavirus–Related Cancer Rates"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Designing and implementing targeted interventions to increase uptake and
      completion of HPV vaccination series across counties with low HPV
      vaccination rates may help to reduce future the burden of HPV-related
      cancers.
    explanation: >-
      This population-based study supports HPV vaccination uptake as a strategy
      to reduce future HPV-related cancer burden, which includes HPV-associated
      vulvar carcinoma.
  therapeutic_modality: VACCINE
  target_mechanisms:
  - target: High-Risk HPV Infection
    treatment_effect: INHIBITS
    description: Prophylactic vaccination prevents acquisition and transmission of vaccine-type high-risk HPV infection upstream of HPV-associated VSCC.
  treatment_term:
    preferred_term: vaccination
    term:
      id: NCIT:C15346
      label: Vaccination
    therapeutic_agent:
    - preferred_term: human papillomavirus vaccine
      term:
        id: NCIT:C1951
        label: Human Papilloma Virus Vaccine
- name: Lichen Sclerosus Maintenance Therapy and Lifelong Surveillance
  description: >-
    In vulvar lichen sclerosus, regular topical corticosteroid maintenance and
    long-term follow-up support symptom control, detection of premalignant
    lesions, and risk management in the HPV-independent pathway. This is
    prevention and surveillance of a risk condition, not treatment of invasive VSCC.
  evidence:
  - reference: DOI:10.3389/fmed.2023.1106318
    reference_title: "Lichen sclerosus: The 2023 update"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      early detection of premalignant lesions and a lifelong follow-up are required
    explanation: >-
      The review directly supports lifelong follow-up for the vulvar lichen
      sclerosus cancer-risk context.
  - reference: DOI:10.3389/fmed.2023.1106318
    reference_title: "Lichen sclerosus: The 2023 update"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      one study shows a statistically significant lesser likelihood to develop
      malignancies when TC were regularly used as a prophylactic measure in
      asymptomatic VLS
    explanation: >-
      This supports regular topical-corticosteroid maintenance as a risk-reducing
      association in VLS without claiming randomized proof of cancer prevention.
  target_mechanisms:
  - target: Lichen Sclerosus Inflammatory Microenvironment
    treatment_effect: MODULATES
    description: Maintenance therapy and surveillance manage the inflammatory dermatosis and its long-term malignant-risk context.
  treatment_term:
    preferred_term: topical corticosteroid therapy
    term:
      id: NCIT:C122078
      label: Topical Corticosteroid Therapy
clinical_trials:
- name: NCT05903833
  phase: PHASE_II
  status: RECRUITING
  description: >-
    Phase II trial of pembrolizumab plus lenvatinib in recurrent, persistent,
    metastatic, or locally advanced vulvar cancer not amenable to curative
    surgery or radiotherapy. ClinicalTrials.gov listed status as RECRUITING on
    2026-08-08.
  target_phenotypes:
  - preferred_term: Recurrent, persistent, metastatic, or locally advanced vulvar cancer
  evidence:
  - reference: clinicaltrials:NCT05903833
    reference_title: "Pembrolizumab in Combination With Lenvatinib in Pts With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy"
    supports: SUPPORT
    snippet: >-
      Evaluation of efficacy and safety of pembrolizumab in combination with
      lenvatinib in patients with recurrent, persistent, metastatic or locally
      advanced vulva cancer.
    explanation: >-
      This ClinicalTrials.gov summary directly describes the study population
      and pembrolizumab-lenvatinib intervention.
- name: NCT07101848
  phase: PHASE_II
  status: NOT_RECRUITING
  description: >-
    Phase II randomized trial of cemiplimab maintenance plus best supportive
    care versus best supportive care after first-line platinum chemotherapy in
    advanced or recurrent vulvar squamous cell carcinoma. ClinicalTrials.gov
    listed status as NOT_YET_RECRUITING on 2026-08-08, represented here by the
    schema's NOT_RECRUITING status enum.
  target_phenotypes:
  - preferred_term: Advanced or recurrent vulvar squamous cell carcinoma
  evidence:
  - reference: clinicaltrials:NCT07101848
    reference_title: "A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER"
    supports: SUPPORT
    snippet: >-
      This is a phase II, randomized study that will include 42 participants
      who have received 4 to 6 cycles of first-line platinum-based
      chemotherapy for advanced vulvar squamous cell carcinoma (SCC) not
      amenable to curative surgical treatment (FIGO 2018 stages III-IV -
      International Federation of Gynecology and Obstetrics) /
    explanation: >-
      This ClinicalTrials.gov summary supports the trial design and population
      for cemiplimab maintenance in advanced or recurrent VSCC.
- name: NCT07290894
  phase: PHASE_II
  status: RECRUITING
  description: >-
    Phase II single-arm, multi-cohort trial of lenvatinib plus pembrolizumab in
    patients with vulvar cancer. ClinicalTrials.gov listed status as RECRUITING
    on 2026-08-08.
  target_phenotypes:
  - preferred_term: Vulvar cancer
  evidence:
  - reference: clinicaltrials:NCT07290894
    reference_title: "Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01 Study."
    supports: SUPPORT
    snippet: >-
      MITO VULVA-1 is a prospective, single arm, multi-cohorts, phase II trial
      that aims to assess the activity and the safety of Lenvatinib plus
      Pembrolizumab in patients with vulvar cancer.
    explanation: >-
      This ClinicalTrials.gov summary directly supports the MITO VULVA-01 trial
      and intervention for patients with vulvar cancer.
experimental_models:
- name: VCC1 Lichen-Sclerosus-Associated VSCC Cell Line
  description: >-
    VCC1 is a spontaneously immortalized human vulvar squamous carcinoma cell
    line derived from lichen-sclerosus-associated VSCC. Three-dimensional
    organotypic cultures and xenografts make it useful for studying tumor-stroma
    dependence, invasion, and drug response.
  experimental_model_type: CELL_LINE
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  tissue_term:
    preferred_term: vulva
    term:
      id: UBERON:0000997
      label: mammalian vulva
  cell_types:
  - preferred_term: vulvar squamous carcinoma cell
    term:
      id: CL:0000312
      label: keratinocyte
  - preferred_term: cancer-associated fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  cell_source: Spontaneously immortalized VCC1 cells isolated from a human lichen-sclerosus-associated VSCC.
  culture_system: Monolayer culture and three-dimensional fibroblast-containing organotypic culture, complemented by xenografts.
  publication: PMID:31654625
  modeled_mechanisms:
  - target: Fibroblast-Supported Tumor Invasion
    description: Tests whether cancer-associated fibroblasts support VSCC invasion and tumor formation.
    evidence:
    - reference: PMID:31654625
      reference_title: "Establishment of a novel cancer cell line derived from vulvar carcinoma associated with lichen sclerosus exhibiting a fibroblast-dependent tumorigenic potential."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        In vitro 3D organotypic assays and in vivo xenografts revealed a prominent
        role of cancer-associated fibroblasts in VCC1 invasion and tumor formation.
      explanation: >-
        The organotypic arm links this in vitro model to fibroblast-supported
        VCC1 invasion.
    - reference: PMID:31654625
      reference_title: "Establishment of a novel cancer cell line derived from vulvar carcinoma associated with lichen sclerosus exhibiting a fibroblast-dependent tumorigenic potential."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        In vitro 3D organotypic assays and in vivo xenografts revealed a prominent
        role of cancer-associated fibroblasts in VCC1 invasion and tumor formation.
      explanation: >-
        The xenograft arm links the model to fibroblast-supported tumor formation
        in vivo.
  findings:
  - statement: >-
      VCC1 retains epithelial morphology and well-differentiated keratinizing
      squamous carcinoma histology resembling the source tumor.
    supporting_text: >-
      Detailed characterization of the novel spontaneously immortalized cell
      line, VCC1 revealed a characteristic epithelial morphology in vitro and a
      well-differentiated keratinizing SCC histology in vivo, closely resembling
      the tumor of origin.
  - statement: >-
      VCC1 shows increased epithelial-mesenchymal-transition markers and
      clonogenic properties relative to established non-VLS-VSCC lines.
    supporting_text: >-
      VCC1 expressed higher levels of epithelial-mesenchymal transition markers
      and higher clonogenic properties as compared to other established non
      VLS-VSCC cell lines.
  evidence:
  - reference: PMID:31654625
    reference_title: "Establishment of a novel cancer cell line derived from vulvar carcinoma associated with lichen sclerosus exhibiting a fibroblast-dependent tumorigenic potential."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In vitro 3D organotypic assays and in vivo xenografts revealed a prominent
      role of cancer-associated fibroblasts in VCC1 invasion and tumor formation.
    explanation: >-
      The in vitro organotypic component supports VCC1 as a model of
      fibroblast-dependent invasion.
  - reference: PMID:31654625
    reference_title: "Establishment of a novel cancer cell line derived from vulvar carcinoma associated with lichen sclerosus exhibiting a fibroblast-dependent tumorigenic potential."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In vitro 3D organotypic assays and in vivo xenografts revealed a prominent
      role of cancer-associated fibroblasts in VCC1 invasion and tumor formation.
    explanation: >-
      The in vivo xenograft component supports VCC1 as a model of
      fibroblast-dependent tumor formation.
discussions:
- discussion_id: gap_vulvar_carcinoma_caf_model_subtype_generality
  prompt: >-
    Is cancer-associated-fibroblast dependence a shared invasion mechanism
    across HPV-associated, HPV-independent p53-abnormal, and HPV-independent
    p53-wild-type VSCC, or is the VCC1 result specific to one
    lichen-sclerosus-associated tumor model?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Fibroblast-Supported Tumor Invasion
  - experimental_models#VCC1 Lichen-Sclerosus-Associated VSCC Cell Line
  rationale: >-
    The current experimental evidence comes from one spontaneously immortalized
    lichen-sclerosus-associated cell line studied in organotypic culture and
    xenografts. That model supports stromal dependence in VCC1 but cannot by
    itself establish generality across the three molecular VSCC subtypes or
    distinguish patient-specific from subtype-shared fibroblast effects.
  proposed_experiments:
  - experiment_id: exp_vscc_subtype_stratified_organoid_caf_panel
    name: Subtype-stratified patient-derived VSCC organoid and CAF perturbation panel
    description: >-
      Establish multiple patient-derived tumor organoids from each major VSCC
      molecular subtype and compare matched CAF addition, depletion, and
      cross-over coculture under a harmonized invasion assay.
    experiment_type:
      preferred_term: patient-derived tumor organoid coculture perturbation experiment
    model_systems:
    - name: Subtype-stratified patient-derived VSCC organoid-CAF coculture panel
      description: >-
        Replicate organoid lines from HPV-associated p16-positive,
        HPV-independent p53-abnormal, and HPV-independent p53-wild-type tumors,
        each paired with matched primary CAFs and normal-vulvar fibroblasts.
      experimental_model_type: CO_CULTURE
      organism:
        preferred_term: human
        term:
          id: NCBITaxon:9606
          label: Homo sapiens
      tissue_term:
        preferred_term: vulva
        term:
          id: UBERON:0000997
          label: mammalian vulva
      cell_types:
      - preferred_term: vulvar squamous carcinoma cell
        term:
          id: CL:0000312
          label: keratinocyte
      - preferred_term: cancer-associated fibroblast
        term:
          id: CL:0000057
          label: fibroblast
      cell_source: Fresh patient VSCC resections and matched tumor-adjacent stromal tissue, stratified by p16, p53, and direct HPV status.
      culture_system: Three-dimensional tumor organoids in matrix with matched, depleted, or cross-over primary fibroblast coculture.
    perturbations:
    - name: Matched CAF addition or depletion
      target: pathophysiology#Fibroblast-Supported Tumor Invasion
      description: >-
        Compare tumor organoids with matched CAFs, without fibroblasts, and with
        normal-vulvar fibroblasts to isolate stromal dependence.
    - name: Cross-subtype CAF exchange
      target: pathophysiology#Fibroblast-Supported Tumor Invasion
      description: >-
        Exchange CAFs among molecular-subtype organoids to distinguish a shared
        fibroblast program from subtype-matched or patient-specific effects.
    readouts:
    - name: Three-dimensional invasion and organoid growth
      target: pathophysiology#Fibroblast-Supported Tumor Invasion
      description: Quantified invasion distance, invasive area, and organoid growth over time.
      assays:
      - preferred_term: three-dimensional invasion assay
      direction: POSITIVE
    - name: Histologic and transcriptional stromal-response fidelity
      target: pathophysiology#Fibroblast-Supported Tumor Invasion
      description: >-
        Keratinizing morphology, epithelial-mesenchymal-transition markers, and
        single-cell tumor/CAF programs compared across subtypes and conditions.
      assays:
      - preferred_term: histopathologic assessment
      - preferred_term: single-cell transcriptomic profiling
      direction: POSITIVE
    controls:
    - name: Tumor organoid without fibroblasts
      description: Establishes the fibroblast-independent invasion and growth baseline for each patient line.
    - name: Normal-vulvar fibroblast coculture
      description: Distinguishes a cancer-associated fibroblast effect from nonspecific stromal support.
    - name: VCC1 organotypic benchmark
      description: Reproduces the published single-line result as a positive benchmark without treating it as subtype-representative.
    decision_criterion: >-
      A shared CAF-dependence mechanism is supported if CAF addition reproducibly
      increases invasion across independent lines in all three subtypes and CAF
      depletion reverses it relative to matched controls. Subtype restriction is
      supported if the effect replicates only within one molecular group;
      failure to reproduce beyond VCC1 would refute cross-subtype generality.
    would_support:
    - pathophysiology#Fibroblast-Supported Tumor Invasion
  evidence:
  - reference: PMID:31654625
    reference_title: "Establishment of a novel cancer cell line derived from vulvar carcinoma associated with lichen sclerosus exhibiting a fibroblast-dependent tumorigenic potential."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In vitro 3D organotypic assays and in vivo xenografts revealed a prominent
      role of cancer-associated fibroblasts in VCC1 invasion and tumor formation.
    explanation: >-
      The organotypic arm motivates the gap by demonstrating CAF-dependent VCC1
      invasion in vitro while leaving cross-subtype reproducibility untested.
  - reference: PMID:31654625
    reference_title: "Establishment of a novel cancer cell line derived from vulvar carcinoma associated with lichen sclerosus exhibiting a fibroblast-dependent tumorigenic potential."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In vitro 3D organotypic assays and in vivo xenografts revealed a prominent
      role of cancer-associated fibroblasts in VCC1 invasion and tumor formation.
    explanation: >-
      The xenograft arm motivates the same gap by demonstrating CAF-dependent
      VCC1 tumor formation in vivo while leaving cross-subtype generality untested.

📚

References & Deep Research

Deep Research

1

Falcon ▸

Vulvar Carcinoma (Vulvar Cancer): Disease Characteristics Research Report

Edison Scientific Literature 60 citations 2026-05-07T15:26:17.300658

Vulvar Carcinoma (Vulvar Cancer): Disease Characteristics Research Report

Target Disease

Disease name: Vulvar carcinoma (vulvar cancer)
Category: Malignant neoplasm of the vulva (female genital tract cancer)
MONDO ID: Not available from the retrieved sources in this run (would require dedicated ontology lookup).

1. Disease Information

Overview (what is the disease?)

Vulvar carcinoma is an uncommon malignant tumor arising in vulvar tissues; vulvar squamous cell carcinoma (VSCC) is the predominant histologic subtype (≈90% of vulvar cancers in multiple reviews). (corte2024currentpreoperativemanagement pages 1-2)

Key identifiers and terminologies

ICD-10: C51 (vulval/vulvar cancer) is explicitly used in health system cost and epidemiology analyses. (steinkasserer2023characterizationofpatients pages 1-2)
ICD-O-3 site coding: HPV-related cancer epidemiology work referenced ICD-O-3 site codes including C51.0 for vulvar cancer. (adekanmbi2024humanpapillomavirusvaccination pages 1-2)
MeSH (term): A 2024 imaging review searched PubMed using MeSH terms including “vulval neoplasm” (and “diagnostic imaging”). (ha2024imaginginvulval pages 1-2)
FIGO staging: The FIGO 2021 revision is data-derived and explicitly allows incorporation of cross-sectional imaging findings into staging. (olawaiye2021figostagingfor pages 1-2)

Common synonyms / alternative names

Vulvar carcinoma; vulval cancer; vulvar cancer; vulvar squamous cell carcinoma (VSCC) (dominant histology). (corte2024currentpreoperativemanagement pages 1-2)

Evidence-source note (individual patient vs aggregated)

This report is derived from aggregated disease-level resources (reviews, guidelines syntheses, cohort/registry studies, and clinical trial registry entries) plus some single-center retrospective cohorts and experimental model studies. (corte2024currentpreoperativemanagement pages 1-2, dongre2024tp53mutationand pages 1-2, meng2024overallsurvivalassociated pages 1-2, dongre2020establishmentofa pages 1-7)

2. Etiology

Core causal pathways (current understanding)

Modern classification recognizes two main etiologic pathways for VSCC: 1. HPV-associated VSCC: often basaloid/warty morphology; typically p16 “block” positive; generally occurs in younger patients and is associated with precursor high-grade squamous intraepithelial lesions (HSIL/usual VIN). (dongre2024tp53mutationand pages 1-2, horn2024molecularsubtypesof pages 12-14, hohn20212020whoclassification pages 4-6) 2. HPV-independent VSCC: often keratinizing morphology; frequently linked to chronic inflammatory vulvar dermatoses (notably lichen sclerosus) and to differentiated VIN (dVIN); commonly shows aberrant p53 patterns consistent with TP53 alteration; generally associated with poorer prognosis. (dongre2024tp53mutationand pages 1-2, horn2024molecularsubtypesof pages 12-14, horn2024molecularsubtypesof pages 16-18)

A recent focus is the less common HPV-independent/p53-wild-type subtype, emphasizing that not all HPV-independent tumors are p53-abnormal. (horn2024molecularsubtypesof pages 12-14)

Risk factors

Infectious: high-risk HPV infection is a major risk factor for HPV-associated disease; HPV16 is predominant among HPV-positive high-grade vulvar lesions in one 2024 review (HPV16 ≈80% of HPV-positive cases). (scurtu2024squamouscellcarcinoma pages 5-7)

Inflammatory/dermatologic: lichen sclerosus (LS) is strongly associated with HPV-independent precancers and cancer and can lead to SCC development; LS causes chronic inflammation and tissue remodeling that may support carcinogenesis. (luca2023lichensclerosusthe pages 1-2, scurtu2024squamouscellcarcinoma pages 5-7)

Precursor lesions: differentiated VIN (dVIN) is a high-risk HPV-independent precursor; one 2024 review reports much higher progression for dVIN than HSIL (43.2% vs 9.7%). (scurtu2024squamouscellcarcinoma pages 4-5)

Host factors: immunosuppression is highlighted as a critical cofactor for HPV-associated lesions in a recent review. (scurtu2024squamouscellcarcinoma pages 5-7)

Protective factors

HPV vaccination: Multiple sources support prophylactic HPV vaccination as a key protective factor against HPV-associated disease, with very high efficacy in HPV-naïve individuals. - A large 2024 cross-sectional study notes vaccine efficacy “close to 100%” for preventing HPV-associated cancers among those without prior infection with vaccine HPV types. (adekanmbi2024humanpapillomavirusvaccination pages 1-2) - A 2024 review of HPV vaccine strategies states that vaccination blocks transmission and prevents HPV-related cancers and reports global implementation but limited coverage (143 member states by end of 2023; ~15% of young girls vaccinated). (cai2024humanpapillomavirusrelatedcancer pages 1-2)

Management of lichen sclerosus (risk reduction plausibility): LS reviews and cohorts emphasize the need for early diagnosis, adequate treatment, and follow-up to reduce malignant evolution risk. - A 2024 LS review reports markedly elevated vulvar cancer risk in LS (example population-based SIR 33.6 for vulvar cancer) and suggests that consistent long-term potent topical corticosteroid (TCS) use may reduce recurrence compared with historical recurrence rates. (popa2024vulvarlichensclerosus pages 21-22)

Gene–environment interactions

Direct quantitative gene–environment interaction estimates were not present in the retrieved evidence. Mechanistically, LS-associated chronic inflammation/oxidative stress provides an enabling microenvironment for carcinogenesis and can co-occur with TP53 pathway alterations typical of HPV-independent disease. (luca2023lichensclerosusthe pages 1-2, scurtu2024squamouscellcarcinoma pages 5-7)

3. Phenotypes (clinical presentation, signs/symptoms, QoL)

Common presenting symptoms/signs (VSCC)

Recent clinical updates emphasize that presentation ranges from asymptomatic lesions detected on exam to symptomatic disease with: - vulvar pruritus (itching) - pain/burning - lump/mass - ulcer These features are highlighted in recent clinical overviews and updates. (corte2024currentpreoperativemanagement pages 1-2, olawaiye2021cancerofthe pages 1-2)

Age of onset / demographics

VSCC predominantly affects postmenopausal women with mean/median ages often >65–70 years in clinical series and reviews; HPV-associated cases skew younger. (corte2024currentpreoperativemanagement pages 1-2, cebollaverdugo2024multidisciplinaryvulvarcancer pages 2-4, dongre2024tp53mutationand pages 1-2)

Quality-of-life impacts

Major QoL burdens stem from symptoms (pain/pruritus), genital functional impairment, and treatment morbidity. - Conservative approaches (e.g., sentinel node biopsy) are emphasized to reduce long-term morbidity such as chronic lymphedema, wound issues, and sexual dysfunction. (cebollaverdugo2024multidisciplinaryvulvarcancer pages 2-4, kolk2024updateonthe pages 1-2)

Suggested HPO terms (examples)

(These are ontology suggestions; HPO IDs are provided where commonly used—verify in HPO browser for exact IDs.) - Pruritus (HP:0000989) - Vulvar pain (term exists in HPO; verify exact ID) - Genital ulcer (HP:0000211, general mucosal ulceration; vulvar-specific term should be checked) - Vulvar mass (term exists; verify exact ID) - Lymphedema (HP:0001004) (treatment complication) (cebollaverdugo2024multidisciplinaryvulvarcancer pages 2-4) - Dyspareunia (HP:0000148) (common in LS and survivorship context) (luca2023lichensclerosusthe pages 1-2)

4. Genetic / Molecular Information

Molecular classification and defining biomarkers

WHO-era classification of vulvar SCC emphasizes HPV association using p16 as a surrogate marker and p53 immunophenotyping for HPV-independent disease (with a recognized “uncertain” group). (hohn20212020whoclassification pages 4-6, horn2024molecularsubtypesof pages 16-18)

HPV-associated: p16 block-positive; often p53 wild-type pattern; typically better prognosis/radiosensitivity. (hohn20212020whoclassification pages 4-6)
HPV-independent: often p16 negative/non-block; frequently p53 aberrant (overexpression, null, cytoplasmic) consistent with TP53 alteration. (horn2024molecularsubtypesof pages 16-18)

Recurrent somatic alterations (VSCC)

2024 Japanese VSCC genomic profiling: TP53 (52–81%), HRAS (7–26%), CDKN2A (21–24%), PIK3CA (5–10%). (fujii2024genomicprofilesof pages 1-2)

HPV-status–linked molecular profiles (tumor sequencing cohort): HPV-independent tumors show high rates of TP53, TERT promoter, CDKN2A, NOTCH1, FAT1 alterations, while HPV-associated tumors are enriched for activating PIK3CA mutations (PI3K pathway). (salama2022molecularlandscapeof pages 1-3)

Mechanistic/pathway summary (causal chain)

HPV-associated pathway: viral oncoproteins (E6/E7/E5) enable immune evasion and drive carcinogenesis; E6/E7 disrupt tumor suppressor pathways, with downstream cell-cycle dysregulation and p16 overexpression. (scurtu2024squamouscellcarcinoma pages 5-7)
HPV-independent pathway: chronic inflammation (e.g., LS) and precursor dVIN are linked to TP53 mutagenic processes, NOTCH1 loss-of-function, and RTK/RAS/PI3K signaling (including HRAS involvement), driving clonal expansion and invasion. (scurtu2024squamouscellcarcinoma pages 5-7, fujii2024genomicprofilesof pages 1-2)

Suggested GO biological process terms (examples)

Epithelial cell proliferation (GO:0050673)
Keratinocyte differentiation (GO:0030216)
Cell cycle regulation (GO:0051726)
DNA damage response (GO:0006974)
Regulation of apoptotic process (GO:0042981)
Response to virus (GO:0009615) (HPV-associated)

Suggested CL (cell type) terms (examples)

Keratinocyte (CL:0000312)
Fibroblast / cancer-associated fibroblast (CL:0000057; CAF is a functional state) (dongre2020establishmentofa pages 1-7)
CD8-positive, alpha-beta T cell (CL:0000625) (prognostic immune infiltrate context) (zhang2023anintegratedmodel pages 1-2)

5. Environmental Information

Infectious agents

High-risk HPV is a key infectious driver of the HPV-associated VSCC pathway. (dongre2024tp53mutationand pages 1-2, scurtu2024squamouscellcarcinoma pages 5-7)

Lifestyle factors

Smoking is cited as a risk factor in clinical updates and reviews. (olawaiye2021cancerofthe pages 1-2)

Non-infectious inflammatory conditions

Chronic inflammatory vulvar dermatoses, especially lichen sclerosus, are strongly linked to HPV-independent carcinogenesis and functional morbidity. (luca2023lichensclerosusthe pages 1-2)

6. Mechanism / Pathophysiology

Key mechanisms and pathways

PI3K/AKT/mTOR signaling: implicated particularly in HPV-associated tumors via PIK3CA activating mutations, and in a subset of HPV-independent cases. (salama2022molecularlandscapeof pages 1-3, fujii2024genomicprofilesof pages 1-2)
RAS/MAPK signaling: HRAS mutations occur in a subset of VSCC. (fujii2024genomicprofilesof pages 1-2)
TP53 tumor suppressor pathway: frequently altered in HPV-independent VSCC and linked to worse prognosis. (dongre2024tp53mutationand pages 1-2, fujii2024genomicprofilesof pages 1-2)
NOTCH pathway: frequently altered in HPV-independent disease in sequencing cohorts, consistent with altered squamous differentiation programs. (salama2022molecularlandscapeof pages 1-3)

Tumor microenvironment and stromal dependence

Experimental evidence supports a strong role for tumor–stroma interaction: a LS-associated VSCC cell line (VCC1) showed fibroblast-dependent invasion and tumor formation in 3D organotypic models and xenografts. (dongre2020establishmentofa pages 1-7)

7. Anatomical Structures Affected

Organ / tissue level

Primary site: vulva (labia majora/minora, clitoris, perineum, mons). (corte2024currentpreoperativemanagement pages 1-2)
Regional spread: lymphatic drainage primarily to inguinofemoral nodes, secondarily to pelvic nodes. (olawaiye2021cancerofthe pages 1-2)

Suggested UBERON terms (examples)

Vulva (UBERON:0000997)
Labium majus (UBERON:0003185)
Labium minus (UBERON:0003186)
Clitoris (UBERON:0002256)
Inguinal lymph node (UBERON:0001542)

8. Temporal Development

Onset: typically adult/geriatric; HPV-associated pathway tends to present earlier than HPV-independent. (dongre2024tp53mutationand pages 1-2)
Progression and precursors: HSIL/uVIN and dVIN are recognized precursors; dVIN has higher malignant potential and faster progression than HSIL in comparative data summarized by reviews. (scurtu2024squamouscellcarcinoma pages 4-5)

9. Inheritance and Population

Epidemiology (selected recent statistics)

A 2024 imaging review cites 47,000 global vulvar cancer cases in 2022. (ha2024imaginginvulval pages 1-2)
A single-center “patterns of care” study cites GLOBOCAN 2020 estimates (45,240 cases; 17,427 deaths). (singhal2024patternsofcare pages 1-2)

Genetic inheritance is not applicable in a Mendelian sense for most vulvar carcinoma; this is primarily a sporadic, multifactorial cancer with somatic driver alterations.

10. Diagnostics

Diagnostic approach

Biopsy of any suspicious vulvar lesion is emphasized as essential for diagnosis; vulvoscopy is a key clinical tool. (corte2024currentpreoperativemanagement pages 1-2, olawaiye2021cancerofthe pages 1-2)

Biomarkers used in practice

p16 immunohistochemistry is used as a surrogate for HPV association; diffuse “block” staining supports HPV-associated neoplasia. (dongre2024tp53mutationand pages 1-2, hohn20212020whoclassification pages 4-6)
p53 immunohistochemistry helps identify HPV-independent/TP53-altered tumors and precursor lesions such as dVIN. (horn2024molecularsubtypesof pages 16-18)

Imaging (preoperative and staging)

Imaging recommendations vary by stage and clinical question; a 2024 preoperative management review identifies MRI and PET as gold-standard imaging for local extension and nodal evaluation, with expert-performed ultrasound increasingly used for groin node assessment. (corte2024currentpreoperativemanagement pages 1-2)

The FIGO 2021 staging revision explicitly allows staging to incorporate cross-sectional imaging findings. (olawaiye2021figostagingfor pages 1-2)

The following table (from the 2024 imaging review) summarizes FIGO 2021 staging.

(ha2024imaginginvulval media e360c86b)

Differential diagnosis (selected)

Vulvar lesions that can mimic malignant or premalignant disease include inflammatory dermatoses (e.g., lichen sclerosus) and premalignant vulvar intraepithelial lesions; biopsy is required when neoplasia is suspected. (luca2023lichensclerosusthe pages 1-2)

11. Outcome / Prognosis

Prognostic factors

Nodal status is critical: one systematic review states 5-year OS is >80% node-negative, <40% with inguinal node involvement, and 10–15% with pelvic nodes. (ferrari2024adjuvantradiotherapyfor pages 1-2)
Molecular subtype impacts prognosis: TP53 mutation status is an independent adverse prognostic factor for progression-free survival, and transcriptionally active hrHPV is associated with improved outcomes in a 2024 cohort. (dongre2024tp53mutationand pages 1-2)

Recent quantitative survival / outcome statistics

SEER-derived survival cited in a guideline comparison: 5-year survival 85.6% localized, 47.5% regional, 23.3% distant (stage IVB). (restaino2025managementofpatients pages 2-4)
A single-center cohort (n=82) reported: disease-specific recurrence 32.9%, mortality 30.5%, median DFS 17 months, median OS 27 months. (singhal2024patternsofcare pages 1-2)
In metastatic vulvar cancer (SEER 2000–2019), chemoradiotherapy improved OS vs radiotherapy alone (matched cohort HR 0.7367, 95% CI 0.5906–0.9190). (meng2024overallsurvivalassociated pages 1-2)

12. Treatment

Current standard-of-care (real-world implementations)

Surgery - Early-stage disease: local excision / radical local excision with attention to margins, plus groin staging when indicated. (kolk2024updateonthe pages 1-2, ferrari2024adjuvantradiotherapyfor pages 1-2)

Sentinel lymph node biopsy (SLNB) - SLNB is an established, less morbid alternative to inguinofemoral lymphadenectomy in selected early-stage VSCC; it reduces complications such as lymphedema while maintaining oncologic safety. (kolk2024updateonthe pages 1-2)

Radiotherapy / chemoradiotherapy - Adjuvant radiotherapy for nodal disease has limited RCT evidence but suggests reduction in cancer-related deaths and groin recurrences; one RCT reported 6-year cancer-related deaths 29% vs 51% (HR 0.49) and groin recurrences 5.3% vs 24.1% favoring radiotherapy. (ferrari2024adjuvantradiotherapyfor pages 1-2) - For locally advanced unresectable disease, multiple guideline sets recommend definitive chemoradiation. (restaino2025managementofpatients pages 14-16)

Systemic therapy and immunotherapy (emerging) - Modern guidance notes emerging immunotherapy options for advanced disease, but evidence remains limited and often extrapolated from other SCC sites; clinical trials are ongoing. (restaino2025managementofpatients pages 2-4)

Active / planned clinical trials (selected)

NCT07101848 (BRAVA VULVAR): Phase II randomized maintenance cemiplimab vs best supportive care after 1st-line platinum chemotherapy in advanced/recurrent vulvar cancer; primary endpoint PFS at week 24; not yet recruiting; estimated start 2025-11-01. URL: https://clinicaltrials.gov/study/NCT07101848 (NCT07101848 chunk 1)
NCT05903833: Phase II single-arm pembrolizumab + lenvatinib in recurrent/metastatic/locally advanced VSCC not amenable to curative surgery/radiotherapy; primary endpoint ORR within 24 weeks; recruiting; start 2025-06-24. URL: https://clinicaltrials.gov/study/NCT05903833 (NCT05903833 chunk 1)
NCT07290894 (MITO VULVA-01): Phase II single-arm multi-cohort pembrolizumab + lenvatinib across unresectable locally advanced, chemo-naïve metastatic, and post-chemo recurrent/metastatic cohorts; primary endpoint ORR by RECIST 1.1; recruiting; start 2026-03-12. URL: https://clinicaltrials.gov/study/NCT07290894 (NCT07290894 chunk 1)

MAXO (Medical Action Ontology) suggestions (examples)

(Provide as ontology suggestions; confirm IDs in MAXO.) - Surgical excision / wide local excision; radical vulvectomy - Sentinel lymph node biopsy - External beam radiotherapy - Concurrent chemoradiotherapy - Immune checkpoint inhibitor therapy (anti–PD-1)

13. Prevention

Primary prevention

HPV vaccination is the primary preventive tool for HPV-associated vulvar precancers/cancers, with very high efficacy in HPV-naïve individuals and broad global adoption but incomplete coverage. (adekanmbi2024humanpapillomavirusvaccination pages 1-2, cai2024humanpapillomavirusrelatedcancer pages 1-2)

Secondary/tertiary prevention

There is no population screening program for vulvar cancer; prevention relies on early identification and management of predisposing conditions/precursors and biopsy of suspicious lesions. (olawaiye2021cancerofthe pages 1-2)
For LS, long-term potent topical corticosteroids are standard and cohorts/reviews emphasize surveillance; LS has strong symptom burden and elevated malignancy risk. (luca2023lichensclerosusthe pages 1-2, popa2024vulvarlichensclerosus pages 21-22)

14. Other Species / Natural Disease

No naturally occurring non-human species disease data were identified in the retrieved sources for vulvar carcinoma specifically.

15. Model Organisms / Experimental Models

Cell lines, organotypic models, xenografts

A LS-associated VSCC cell line (VCC1) was established and shown to have fibroblast-dependent tumorigenic and invasive behavior in 3D collagen co-culture/organotypic assays and xenografts, highlighting cancer-associated fibroblast contributions. URL: https://doi.org/10.1016/j.yexcr.2019.111684 (Published Jan 2020). (dongre2020establishmentofa pages 1-7)
The A431 cell line is used as a vulvar SCC model in mechanistic studies; one report shows miR-4712-5p promotes proliferation/invasion by targeting PTEN and activating AKT/cyclin D1 signaling. URL: https://doi.org/10.3892/or.2019.7320 (Published Sep 2019). (yang2019microrna47125ppromotesproliferation pages 1-2)

Suggested uses

Tumor–stroma interaction experiments (CAF co-culture)
Pathway perturbation (PI3K/AKT, RAS/MAPK)
Immunotherapy biomarker exploration (PD-L1, TILs) and radiosensitivity hypotheses by subtype

Summary artifact (identifiers, subtypes, genomics)

Section	Item	Summary	Notes/Citations
Identifiers/terminology	Standard disease name	Vulvar carcinoma / vulval cancer; most cases are vulvar squamous cell carcinoma (VSCC), the predominant histology (~90%).	ICD-10 C51 is reported for vulval cancer; VSCC predominance noted in recent reviews (corte2024currentpreoperativemanagement pages 1-2)
Identifiers/terminology	Controlled vocabulary / search term	A 2024 imaging review explicitly used the MeSH search terms “vulval neoplasm” and “diagnostic imaging.”	Useful for literature retrieval, though no MeSH UID was provided in retrieved text (ha2024imaginginvulval pages 1-2)
Identifiers/terminology	Staging/classification	FIGO 2021 is the current staging framework for vulvar carcinoma and permits incorporation of cross-sectional imaging into staging.	Data-derived revision; imaging incorporation specifically noted (olawaiye2021figostagingfor pages 1-2, ha2024imaginginvulval pages 1-2, faruqiUnknownyear2021figostaging pages 1-5)
Identifiers/terminology	ICD-related coding context	Additional ICD-related references in retrieved literature include ICD-10 groupings for vulvar cancer and ICD-O-3 site code C51.0 in HPV-related cancer analyses.	ICD-10 C51 reported in economic analysis; ICD-O-3 C51.0 cited in HPV-related cancer rate study (steinkasserer2023characterizationofpatients pages 1-2, adekanmbi2024humanpapillomavirusvaccination pages 1-2)
Molecular subtype	HPV-associated VSCC	Typically younger women; often basaloid/warty morphology; precursor lesions are HSIL/uVIN (usual-type VIN); usually block-positive p16, generally non-aberrant/wild-type p53 pattern; often better prognosis and better radiotherapy response.	HPV-associated tumors usually occur in younger patients and have improved prognosis/radiosensitivity (dongre2024tp53mutationand pages 1-2, horn2024molecularsubtypesof pages 12-14, hohn20212020whoclassification pages 4-6, scurtu2024squamouscellcarcinoma pages 5-7)
Molecular subtype	HPV-independent, p53-abnormal VSCC	Typically older/postmenopausal women; usually keratinizing morphology; precursor lesions are dVIN and often lichen sclerosus; usually p16 negative/non-block with aberrant p53 (overexpression, null, or cytoplasmic pattern); generally worse prognosis and less radiosensitive.	Strongly associated with TP53 alterations, poorer outcomes, and lower radiosensitivity (dongre2024tp53mutationand pages 1-2, hohn20212020whoclassification pages 4-6, horn2024molecularsubtypesof pages 16-18)
Molecular subtype	HPV-independent, p53-wild-type VSCC	Uncommon third molecular subtype within HPV-independent disease; lacks HPV association and lacks classic p53-abnormal pattern; still falls within the HPV-independent spectrum but is molecularly distinct and under active study.	Recent 2024 review emphasizes diagnostic/treatment significance of this subtype (horn2024molecularsubtypesof pages 12-14, horn2024molecularsubtypesof pages 1-5)
Biomarker framework	p16 / p53 interpretation	p16 is a surrogate marker of HPV-driven disease; p53 IHC helps identify HPV-independent/TP53-altered disease. Combined p16/p53 stratification supports classification into clinically meaningful subgroups.	WHO/CAP-aligned approach summarized in recent reviews and cohort work (dongre2024tp53mutationand pages 1-2, hohn20212020whoclassification pages 4-6, horn2024molecularsubtypesof pages 16-18, hohn20212020whoclassification pages 1-2)
Genomics: 2024 Japanese cohort	TP53	Most common alteration in Japanese VSCC cohorts: 52–81%.	2024 Scientific Reports cohort; predominantly HPV-independent tumors (fujii2024genomicprofilesof pages 1-2)
Genomics: 2024 Japanese cohort	HRAS	Recurrent alteration: 7–26%.	Suggests RTK/RAS pathway involvement in a subset (fujii2024genomicprofilesof pages 1-2)
Genomics: 2024 Japanese cohort	CDKN2A	Recurrent alteration: 21–24%.	Cell-cycle dysregulation signal (fujii2024genomicprofilesof pages 1-2)
Genomics: 2024 Japanese cohort	PIK3CA	Recurrent alteration: 5–10%.	Supports PI3K pathway targetability in a subset (fujii2024genomicprofilesof pages 1-2)
Genomics: 2022 MSK cohort	HPV-associated profile	Enriched for PIK3CA activating mutations 7/11 (64%); NOTCH-pathway alterations also present 6/11 (55%) but involving different genes than HPV-independent tumors.	HPV-associated tumors favor PI3K-pathway activation (salama2022molecularlandscapeof pages 4-6, salama2022molecularlandscapeof pages 8-10, salama2022molecularlandscapeof pages 1-3)
Genomics: 2022 MSK cohort	HPV-independent profile	Strong enrichment for TERT alterations 14/15 (93%), TP53 13/15 (87%), CDKN2A 10/15 (67%), NOTCH1 7/15 (47%), FAT1 7/15 (47%); NOTCH-pathway alterations overall 10/15 (67%).	Distinct molecular program from HPV-associated tumors; TERT/TP53/CDKN2A/NOTCH1 argue against HPV-driven etiology (salama2022molecularlandscapeof pages 4-6, salama2022molecularlandscapeof pages 8-10, salama2022molecularlandscapeof pages 1-3)
Genomics: additional recent cohort	HPV-independent vs HPV-associated differences	In an additional recent cohort, HPV-negative tumors showed TP53 86% vs 0%, POLE 50% vs 6%, NOTCH1 43% vs 19%, CDKN2A 36% vs 0%; HPV-associated tumors more often had CNVs, especially cMYC, plus CDK2/CDK4 amplifications.	Useful supporting comparison for subtype-specific molecular architecture (farkas2025pathologicalvariantsin pages 8-9, farkas2025pathologicalvariantsin pages 7-8)

Table: This table compiles core identifiers, current subtype terminology, biomarker definitions, and recurrent genomic alterations for vulvar carcinoma/VSCC. It is useful as a compact reference for disease ontology, clinicopathologic stratification, and precision-oncology annotation.

References

(corte2024currentpreoperativemanagement pages 1-2): Luigi Della Corte, Valeria Cafasso, Maria Chiara Guarino, Giuseppe Gullo, Gaspare Cucinella, Alessandra Lopez, Simona Zaami, Gaetano Riemma, Pierluigi Giampaolino, and Giuseppe Bifulco. Current preoperative management of vulvar squamous cell carcinoma: an overview. Cancers, 16:1846, May 2024. URL: https://doi.org/10.3390/cancers16101846, doi:10.3390/cancers16101846. This article has 12 citations.
(steinkasserer2023characterizationofpatients pages 1-2): L. Steinkasserer, J. Hachenberg, P. Hillemanns, and M. Jentschke. Characterization of patients with vulvar lichen sclerosus and association to vulvar carcinoma: a retrospective single center analysis. Archives of Gynecology and Obstetrics, 307:1921-1928, Nov 2023. URL: https://doi.org/10.1007/s00404-022-06848-y, doi:10.1007/s00404-022-06848-y. This article has 20 citations and is from a peer-reviewed journal.
(adekanmbi2024humanpapillomavirusvaccination pages 1-2): Victor Adekanmbi, Itunu Sokale, Fangjian Guo, Jessica Ngo, Thao N. Hoang, Christine D. Hsu, Abiodun Oluyomi, and Abbey B. Berenson. Human papillomavirus vaccination and human papillomavirus–related cancer rates. JAMA Network Open, 7:e2431807, Sep 2024. URL: https://doi.org/10.1001/jamanetworkopen.2024.31807, doi:10.1001/jamanetworkopen.2024.31807. This article has 13 citations and is from a peer-reviewed journal.
(ha2024imaginginvulval pages 1-2): Minah Ha and Lois Eva. Imaging in vulval cancer. Cancers, 16:2269, Jun 2024. URL: https://doi.org/10.3390/cancers16122269, doi:10.3390/cancers16122269. This article has 5 citations.
(olawaiye2021figostagingfor pages 1-2): A. Olawaiye, J. Cotler, M. Cuello, N. Bhatla, A. Okamoto, S. Wilailak, C. Purandare, G. Lindeque, J. Berek, S. Kehoe, S. Kehoe, A. Olawaiye, M. Cuello, N. Bhatla, A. Okamoto, S. Wilailak, G. Lindeque, J. Berek, C. Purandare, and J. Cain. Figo staging for carcinoma of the vulva: 2021 revision. International Journal of Gynaecology and Obstetrics, 155:43-47, Sep 2021. URL: https://doi.org/10.1002/ijgo.13880, doi:10.1002/ijgo.13880. This article has 129 citations.
(dongre2024tp53mutationand pages 1-2): Harsh Nitin Dongre, Rammah Elnour, Stian Tornaas, Siren Fromreide, Liv Cecilie Vestrheim Thomsen, Ingrid Benedicte Moss Kolseth, Elisabeth Sivy Nginamau, Anne Christine Johannessen, Olav Karsten Vintermyr, Daniela Elena Costea, and Line Bjørge. Tp53 mutation and human papilloma virus status as independent prognostic factors in a norwegian cohort of vulva squamous cell carcinoma. Acta Obstetricia et Gynecologica Scandinavica, 103:165-175, Oct 2024. URL: https://doi.org/10.1111/aogs.14689, doi:10.1111/aogs.14689. This article has 14 citations and is from a domain leading peer-reviewed journal.
(meng2024overallsurvivalassociated pages 1-2): Xiaolin Meng, Shuaiqingying Guo, Xue Feng, Jihui Ai, and Jie Yang. Overall survival associated with surgery, radiotherapy, and chemotherapy in metastatic vulvar cancer: a retrospective cohort study based on the seer database. Cancer Pathogenesis and Therapy, 2:195-204, Jul 2024. URL: https://doi.org/10.1016/j.cpt.2023.08.003, doi:10.1016/j.cpt.2023.08.003. This article has 6 citations.
(dongre2020establishmentofa pages 1-7): Harsh Dongre, Neha Rana, Siren Fromreide, Saroj Rajthala, Ingeborg Bøe Engelsen, Justine Paradis, J. Silvio Gutkind, Olav Karsten Vintermyr, Anne Christine Johannessen, Line Bjørge, and Daniela Elena Costea. Establishment of a novel cancer cell line derived from vulvar carcinoma associated with lichen sclerosus exhibiting a fibroblast-dependent tumorigenic potential. Experimental Cell Research, 386:111684, Jan 2020. URL: https://doi.org/10.1016/j.yexcr.2019.111684, doi:10.1016/j.yexcr.2019.111684. This article has 12 citations and is from a peer-reviewed journal.
(horn2024molecularsubtypesof pages 12-14): Lars-Christian Horn, Christine E. Brambs, Blake Gilks, Lien Hoang, Naveena Singh, Ruth GG Hiller, Hering Kathrin, Jessica N McAlpine, Mona Alfaraidi, Bahriye Aktas, Nadja DORNHÖFER, Amy Jamieson, and Anne Kathrin Höhn. Molecular subtypes of vulvar squamous cell carcinoma: the significance of hpv-independent/p53 wild type. Cancers, Dec 2024. URL: https://doi.org/10.3390/cancers16244216, doi:10.3390/cancers16244216. This article has 11 citations.
(hohn20212020whoclassification pages 4-6): Anne Kathrin Höhn, Christine E. Brambs, Grit Gesine Ruth Hiller, Doris May, Elisa Schmoeckel, and Lars-Christian Horn. 2020 who classification of female genital tumors. Geburtshilfe und Frauenheilkunde, 81:1145-1153, Oct 2021. URL: https://doi.org/10.1055/a-1545-4279, doi:10.1055/a-1545-4279. This article has 487 citations and is from a peer-reviewed journal.
(horn2024molecularsubtypesof pages 16-18): Lars-Christian Horn, Christine E. Brambs, Blake Gilks, Lien Hoang, Naveena Singh, Ruth GG Hiller, Hering Kathrin, Jessica N McAlpine, Mona Alfaraidi, Bahriye Aktas, Nadja DORNHÖFER, Amy Jamieson, and Anne Kathrin Höhn. Molecular subtypes of vulvar squamous cell carcinoma: the significance of hpv-independent/p53 wild type. Cancers, Dec 2024. URL: https://doi.org/10.3390/cancers16244216, doi:10.3390/cancers16244216. This article has 11 citations.
(scurtu2024squamouscellcarcinoma pages 5-7): Lucian G. Scurtu, Francesca Scurtu, Sebastian Catalin Dumitrescu, and Olga Simionescu. Squamous cell carcinoma in situ—the importance of early diagnosis in bowen disease, vulvar intraepithelial neoplasia, penile intraepithelial neoplasia, and erythroplasia of queyrat. Diagnostics, 14:1799, Aug 2024. URL: https://doi.org/10.3390/diagnostics14161799, doi:10.3390/diagnostics14161799. This article has 11 citations.
(luca2023lichensclerosusthe pages 1-2): David A. De Luca, Cristian Papara, Artem Vorobyev, Hernán Staiger, Katja Bieber, Diamant Thaçi, and Ralf J. Ludwig. Lichen sclerosus: the 2023 update. Frontiers in Medicine, Feb 2023. URL: https://doi.org/10.3389/fmed.2023.1106318, doi:10.3389/fmed.2023.1106318. This article has 234 citations.
(scurtu2024squamouscellcarcinoma pages 4-5): Lucian G. Scurtu, Francesca Scurtu, Sebastian Catalin Dumitrescu, and Olga Simionescu. Squamous cell carcinoma in situ—the importance of early diagnosis in bowen disease, vulvar intraepithelial neoplasia, penile intraepithelial neoplasia, and erythroplasia of queyrat. Diagnostics, 14:1799, Aug 2024. URL: https://doi.org/10.3390/diagnostics14161799, doi:10.3390/diagnostics14161799. This article has 11 citations.
(cai2024humanpapillomavirusrelatedcancer pages 1-2): Xia Cai and Ling Xu. Human papillomavirus-related cancer vaccine strategies. Vaccines, 12 11:1291, Nov 2024. URL: https://doi.org/10.3390/vaccines12111291, doi:10.3390/vaccines12111291. This article has 14 citations.
(popa2024vulvarlichensclerosus pages 21-22): Adelina Popa, Mihai Dumitrascu, Aida Petca, Razvan-Cosmin Petca, and Florica Sandru. Vulvar lichen sclerosus: navigating sex hormone dynamics and pioneering personalized treatment paradigm. Journal of Personalized Medicine, 14:76, Jan 2024. URL: https://doi.org/10.3390/jpm14010076, doi:10.3390/jpm14010076. This article has 21 citations.
(olawaiye2021cancerofthe pages 1-2): Alexander B. Olawaiye, Mauricio A. Cuello, and Linda J. Rogers. Cancer of the vulva: 2021 update. International Journal of Gynaecology and Obstetrics, 155:7-18, Oct 2021. URL: https://doi.org/10.1002/ijgo.13881, doi:10.1002/ijgo.13881. This article has 247 citations.
(cebollaverdugo2024multidisciplinaryvulvarcancer pages 2-4): Marta Cebolla-Verdugo, Victor Alfredo Cassini-Gómez de Cádiz, Juan Pablo Velasco-Amador, María Zulaika-Lloret, Francisco Manuel Almazán-Fernández, and Ricardo Ruiz-Villaverde. Multidisciplinary vulvar cancer management: the dermatologist’s perspective. Life, 15:19, Dec 2024. URL: https://doi.org/10.3390/life15010019, doi:10.3390/life15010019. This article has 1 citations.
(kolk2024updateonthe pages 1-2): Willemijn L. van der Kolk, Joost Bart, Ate J.G. van der Zee, and Maaike H.M. Oonk. Update on the sentinel node procedure in vulvar cancer. Journal of the National Comprehensive Cancer Network : JNCCN, Mar 2024. URL: https://doi.org/10.6004/jnccn.2024.7002, doi:10.6004/jnccn.2024.7002. This article has 2 citations.
(fujii2024genomicprofilesof pages 1-2): Erisa Fujii, Mayumi Kobayashi Kato, Maiko Yamaguchi, Daiki Higuchi, Takafumi Koyama, Masaaki Komatsu, Ryuji Hamamoto, Mitsuya Ishikawa, Tomoyasu Kato, Takashi Kohno, Kouya Shiraishi, and Hiroshi Yoshida. Genomic profiles of japanese patients with vulvar squamous cell carcinoma. Scientific Reports, Jun 2024. URL: https://doi.org/10.1038/s41598-024-63913-z, doi:10.1038/s41598-024-63913-z. This article has 1 citations and is from a peer-reviewed journal.
(salama2022molecularlandscapeof pages 1-3): Abeer M. Salama, Amir Momeni-Boroujeni, Chad Vanderbilt, Marc Ladanyi, and Robert Soslow. Molecular landscape of vulvovaginal squamous cell carcinoma: new insights into molecular mechanisms of hpv-associated and hpv-independent squamous cell carcinoma. Modern Pathology, 35:274-282, Feb 2022. URL: https://doi.org/10.1038/s41379-021-00942-3, doi:10.1038/s41379-021-00942-3. This article has 44 citations and is from a domain leading peer-reviewed journal.
(zhang2023anintegratedmodel pages 1-2): Tao Zhang, Yingfan Zhu, Jie Luo, Juanqing Li, Shuang Niu, Hao Chen, and Feng Zhou. An integrated model for prognosis in vulvar squamous cell carcinoma. BMC Cancer, Jun 2023. URL: https://doi.org/10.1186/s12885-023-11039-2, doi:10.1186/s12885-023-11039-2. This article has 9 citations and is from a peer-reviewed journal.
(singhal2024patternsofcare pages 1-2): Seema Singhal, Daya Nand Sharma, Sandeep Mathur, Swati Tomar, Jyoti Meena, Anju Singh, and Neerja Bhatla. Patterns of care for vulvar cancer and insights from revised figo staging: a retrospective study. World Journal of Surgical Oncology, Dec 2024. URL: https://doi.org/10.1186/s12957-024-03612-1, doi:10.1186/s12957-024-03612-1. This article has 3 citations and is from a peer-reviewed journal.
(ha2024imaginginvulval media e360c86b): Minah Ha and Lois Eva. Imaging in vulval cancer. Cancers, 16:2269, Jun 2024. URL: https://doi.org/10.3390/cancers16122269, doi:10.3390/cancers16122269. This article has 5 citations.
(ferrari2024adjuvantradiotherapyfor pages 1-2): Federico Ferrari, Lamiese Ismail, Ahmad Sabbagh, Kieran Hardern, Robert Owens, Elisa Gozzini, and Hooman Soleymani Majd. Adjuvant radiotherapy for groin node metastases following surgery for vulvar cancer: a systematic review. Oncology Reviews, May 2024. URL: https://doi.org/10.3389/or.2024.1389035, doi:10.3389/or.2024.1389035. This article has 3 citations.
(restaino2025managementofpatients pages 2-4): Stefano Restaino, Giulia Pellecchia, Martina Arcieri, Giorgio Bogani, Cristina Taliento, Pantaleo Greco, Lorenza Driul, Vito Chiantera, Rosa Pasqualina De Vincenzo, Giorgia Garganese, Francesco Sopracordevole, Violante Di Donato, Andrea Ciavattini, Paolo Scollo, Giovanni Scambia, and Giuseppe Vizzielli. Management of patients with vulvar cancers: a systematic comparison of international guidelines (nccn–asco–esgo–bgcs–igcs–figo–french guidelines–rcog). Cancers, 17:186, Jan 2025. URL: https://doi.org/10.3390/cancers17020186, doi:10.3390/cancers17020186. This article has 23 citations.
(restaino2025managementofpatients pages 14-16): Stefano Restaino, Giulia Pellecchia, Martina Arcieri, Giorgio Bogani, Cristina Taliento, Pantaleo Greco, Lorenza Driul, Vito Chiantera, Rosa Pasqualina De Vincenzo, Giorgia Garganese, Francesco Sopracordevole, Violante Di Donato, Andrea Ciavattini, Paolo Scollo, Giovanni Scambia, and Giuseppe Vizzielli. Management of patients with vulvar cancers: a systematic comparison of international guidelines (nccn–asco–esgo–bgcs–igcs–figo–french guidelines–rcog). Cancers, 17:186, Jan 2025. URL: https://doi.org/10.3390/cancers17020186, doi:10.3390/cancers17020186. This article has 23 citations.
(NCT07101848 chunk 1): A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER. Hospital Israelita Albert Einstein. 2025. ClinicalTrials.gov Identifier: NCT07101848
(NCT05903833 chunk 1): Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy. AGO Research GmbH. 2025. ClinicalTrials.gov Identifier: NCT05903833
(NCT07290894 chunk 1): Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01. National Cancer Institute, Naples. 2026. ClinicalTrials.gov Identifier: NCT07290894
(yang2019microrna47125ppromotesproliferation pages 1-2): Shaojie Yang, Yanyan Zhao, Lufang Wang, Chang Liu, Ye Lu, Zhidong Fang, Hongshuang Shi, Wenyi Zhang, and Xin Wu. Microrna-4712-5p promotes proliferation of the vulvar squamous cell carcinoma cell line a431 by targeting pten through the akt/cyclin d1 signaling pathways. Oncology Reports, 42:1689-1698, Sep 2019. URL: https://doi.org/10.3892/or.2019.7320, doi:10.3892/or.2019.7320. This article has 13 citations and is from a peer-reviewed journal.
(faruqiUnknownyear2021figostaging pages 1-5): BRRGA Faruqi, M Eden, and SSANW Glenn. 2021 figo staging system for vulvar cancer: summary and comparison with 2009 figo staging system. Unknown journal, Unknown year.
(horn2024molecularsubtypesof pages 1-5): Lars-Christian Horn, Christine E. Brambs, Blake Gilks, Lien Hoang, Naveena Singh, Ruth GG Hiller, Hering Kathrin, Jessica N McAlpine, Mona Alfaraidi, Bahriye Aktas, Nadja DORNHÖFER, Amy Jamieson, and Anne Kathrin Höhn. Molecular subtypes of vulvar squamous cell carcinoma: the significance of hpv-independent/p53 wild type. Cancers, Dec 2024. URL: https://doi.org/10.3390/cancers16244216, doi:10.3390/cancers16244216. This article has 11 citations.
(hohn20212020whoclassification pages 1-2): Anne Kathrin Höhn, Christine E. Brambs, Grit Gesine Ruth Hiller, Doris May, Elisa Schmoeckel, and Lars-Christian Horn. 2020 who classification of female genital tumors. Geburtshilfe und Frauenheilkunde, 81:1145-1153, Oct 2021. URL: https://doi.org/10.1055/a-1545-4279, doi:10.1055/a-1545-4279. This article has 487 citations and is from a peer-reviewed journal.
(salama2022molecularlandscapeof pages 4-6): Abeer M. Salama, Amir Momeni-Boroujeni, Chad Vanderbilt, Marc Ladanyi, and Robert Soslow. Molecular landscape of vulvovaginal squamous cell carcinoma: new insights into molecular mechanisms of hpv-associated and hpv-independent squamous cell carcinoma. Modern Pathology, 35:274-282, Feb 2022. URL: https://doi.org/10.1038/s41379-021-00942-3, doi:10.1038/s41379-021-00942-3. This article has 44 citations and is from a domain leading peer-reviewed journal.
(salama2022molecularlandscapeof pages 8-10): Abeer M. Salama, Amir Momeni-Boroujeni, Chad Vanderbilt, Marc Ladanyi, and Robert Soslow. Molecular landscape of vulvovaginal squamous cell carcinoma: new insights into molecular mechanisms of hpv-associated and hpv-independent squamous cell carcinoma. Modern Pathology, 35:274-282, Feb 2022. URL: https://doi.org/10.1038/s41379-021-00942-3, doi:10.1038/s41379-021-00942-3. This article has 44 citations and is from a domain leading peer-reviewed journal.
(farkas2025pathologicalvariantsin pages 8-9): Sanja A. Farkas, Alvida Qvick, Gisela Helenius, and Gabriella Lillsunde-Larsson. Pathological variants in hpv-independent vulvar tumours. Scientific Reports, Jan 2025. URL: https://doi.org/10.1038/s41598-024-84688-3, doi:10.1038/s41598-024-84688-3. This article has 3 citations and is from a peer-reviewed journal.
(farkas2025pathologicalvariantsin pages 7-8): Sanja A. Farkas, Alvida Qvick, Gisela Helenius, and Gabriella Lillsunde-Larsson. Pathological variants in hpv-independent vulvar tumours. Scientific Reports, Jan 2025. URL: https://doi.org/10.1038/s41598-024-84688-3, doi:10.1038/s41598-024-84688-3. This article has 3 citations and is from a peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Definitions

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Biochemical Markers

Diagnosis

Progression

Stages

Prevalence

Infectious Agent

Clinical Trials

Experimental Models

Source YAML

References & Deep Research

Deep Research

Vulvar Carcinoma (Vulvar Cancer): Disease Characteristics Research Report

Target Disease

1. Disease Information

Overview (what is the disease?)

Key identifiers and terminologies

Common synonyms / alternative names

Evidence-source note (individual patient vs aggregated)

2. Etiology

Core causal pathways (current understanding)

Risk factors

Protective factors

Gene–environment interactions

3. Phenotypes (clinical presentation, signs/symptoms, QoL)

Common presenting symptoms/signs (VSCC)

Age of onset / demographics

Quality-of-life impacts

Suggested HPO terms (examples)

4. Genetic / Molecular Information

Molecular classification and defining biomarkers

Recurrent somatic alterations (VSCC)

Mechanistic/pathway summary (causal chain)

Suggested GO biological process terms (examples)

Suggested CL (cell type) terms (examples)

5. Environmental Information

Infectious agents

Lifestyle factors

Non-infectious inflammatory conditions

6. Mechanism / Pathophysiology

Key mechanisms and pathways

Tumor microenvironment and stromal dependence

7. Anatomical Structures Affected

Organ / tissue level

Suggested UBERON terms (examples)

8. Temporal Development

9. Inheritance and Population

Epidemiology (selected recent statistics)

10. Diagnostics

Diagnostic approach

Biomarkers used in practice

Imaging (preoperative and staging)

Differential diagnosis (selected)

11. Outcome / Prognosis

Prognostic factors

Recent quantitative survival / outcome statistics

12. Treatment

Current standard-of-care (real-world implementations)

Active / planned clinical trials (selected)

MAXO (Medical Action Ontology) suggestions (examples)

13. Prevention

Primary prevention

Secondary/tertiary prevention

14. Other Species / Natural Disease

15. Model Organisms / Experimental Models

Cell lines, organotypic models, xenografts

Suggested uses

Summary artifact (identifiers, subtypes, genomics)